


SUBSTITUTE FORM PTO-1390 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER 06501-065001
		U.S. APPLICATION NO. (IF KNOWN) <div style="font-size: 1.5em; font-weight: bold;">09/647772</div>
INTERNATIONAL APPLICATION NO. PCT/JP99/01798	INTERNATIONAL FILING DATE April 5, 1999	PRIORITY DATE CLAIMED April 6, 1998
TITLE OF INVENTION INDOLE DERIVATIVES		
APPLICANT(S) FOR DO/EO/US Noritsugu Yamasaki, Takafumi Imoto, Teruo Oku, Hiroshi Kayakiri, Osamu Onomura and Takahiro Hiramura		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. below concern other documents or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input type="checkbox"/> Other items or information: <div style="margin-left: 20px;"> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> 		

Express Mail[®] mailing label number **EL624270264US**

Date of Deposit October 4, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner For Patents, Washington, D.C. 20231

Samantha Bell
Samantha Bell

U.S. APPLICATION NO. (IF KNOWN) 09/647772		INTERNATIONAL APPLICATION NO. PCT/JP99/01798		ATTORNEY'S DOCKET NUMBER 06501-065001	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)):					
Search report has been prepared by the EPO or JPO..... \$840				\$840.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) .. \$670				\$0.00	
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).... \$690				\$0.00	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970				\$0.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2) to (4) \$96				\$0.00	
ENTER APPROPRIATE BASIC FEE AMOUNT				\$840.00	
Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(e)).				\$0.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	9 - 20	0	x \$18	\$0.00	
Independent Claims	1 - 3	0	x \$78	\$0.00	
Multiple Dependent Claims(s) (if applicable)			+ \$260	\$260.00	
TOTAL OF ABOVE CALCULATIONS				\$260.00	
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28.)				\$0.00	
SUBTOTAL				\$1,100.00	
Processing fee of \$130 for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 mos. from the earliest claimed priority date (37 CFR 1.492(f))				\$0.00	
TOTAL NATIONAL FEE				\$1,100.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).				\$0.00	
TOTAL FEES ENCLOSED				\$1,100.00	
				Amount to be refunded	
				Charged	
a. <input checked="" type="checkbox"/> A check in the amount of \$1,100.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 06-1050 in the amount of \$0.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1050. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Kathleen J. Philpot FISH & RICHARDSON P.C. 225 Franklin Street Boston, MA 02110-2804 (617) 542-5070 phone (617) 542-8906 facsimile			 SIGNATURE Janis K. Fraser NAME 34,819 REGISTRATION NUMBER		

09647772 110602

Attorney's Docket No.: 06501-065001

09/647772

528 Rec'd PCT/PTO 04 OCT 2000

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: INDOLE DERIVATIVES

APPLICANT: TERUO OKU, TAKAFUMI IMOTO, NORITSUGU
YAMASAKI, HIROSHI KAYAKIRI, OSAMU ONOMURA
AND TAKAHIRO HIRAMURA

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL624270264US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 4, 2000
Date of Deposit

Samantha Bell
Signature

Samantha Bell
Typed or Printed Name of Person Signing Certificate

15/PRTS

INDOLE DERIVATIVESTECHNICAL FIELD

The present invention relates to novel indole derivatives, and, more precisely, to novel indole derivatives and their pharmaceutically acceptable salts having blood sugar level-depressing activity or PDE5-inhibiting activity. The present invention also relates to pharmaceutical compositions comprising, as an active ingredient, such indole derivatives or their pharmaceutically acceptable salts.


DISCLOSURE OF THE INVENTION

The subject matter of the present invention is to provide novel indole derivatives and their pharmaceutically acceptable salts, and also pharmaceutical compositions which comprise, as an active ingredient, such indole derivatives or their pharmaceutically acceptable salts, and which are useful for preventing and treating impaired glucose tolerance, diabetes (type II diabetes), diabetic complications (e.g., diabetic gangrene, diabetic arthropathy, diabetic osteopenia, diabetic glomerulosclerosis, diabetic nephropathy, diabetic dermatopathy, diabetic neuropathy, diabetic cataract, diabetic retinopathy, etc.), syndrome of insulin resistance (e.g., insulin receptor disorders, Rabson-Mendenhall syndrome, leprechaunism, Kobberling-Dunnigan syndrome, Seip syndrome, Lawrence syndrome, Cushing syndrome, acromegaly, etc.), polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular disorders (e.g., stenocardia, cardiac failure, etc.), hyperglycemia (e.g., abnormal saccharometabolism such as feeding disorders, etc.), hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy (e.g., diabetic glomerulosclerosis, etc.), tubulointerstitial disorders (e.g., renopathy induced by FK506, cyclosporin, etc.), renal failure, angiostenosis (e.g., after percutaneous arterioplasty), distal angiopathy, cerebral apoplexy, chronic reversible obstructions (e.g., bronchitis, asthma (chronic

asthma, allergic asthma)), autoimmune disease, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders (e.g., hypersensitive enteropathy syndrome, etc.), impotence (e.g., organic impotence, psychic impotence, etc.),
5 nephritis, cachexia (e.g., progressive weight loss due to the lipolysis, myolysis, anemia, edema, anorexia, etc. associated with chronic diseases such as cancer, tuberculosis, endocrine disorder, AIDS, etc.), pancreatitis, or restenosis after PTCA.

The present inventors provide a novel indole derivative
10 represented by the formula (I) and its pharmaceutically acceptable salt, and a pharmaceutical composition comprising said compound or its pharmaceutically acceptable salt as an effective ingredient, which is usable for preventing and treating impaired glucose tolerance, diabetes (type II diabetes), diabetic complications (e.g.,
15 diabetic gangrene, diabetic arthropathy, diabetic osteopenia, diabetic glomerulosclerosis, diabetic nephropathy, diabetic dermatopathy, diabetic neuropathy, diabetic cataract, diabetic retinopathy, etc.), syndrome of insulin resistance (e.g., insulin receptor disorders, Rabson-Mendenhall syndrome, leprechaunism,
20 Kobberling-Dunnigan syndrome, Seip syndrome, Lawrence syndrome, Cushing syndrome, acromegaly, etc.), polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular disorders (e.g., stenocardia, cardiac failure, etc.), hyperglycemia (e.g., abnormal saccharometabolism such as feeding disorders, etc.), hypertension,
25 pulmonary hypertension, congestive heart failure, glomerulopathy (e.g., diabetic glomerulosclerosis, etc.), tubulointerstitial disorders (e.g., renopathy induced by FK506, cyclosporin, etc.), renal failure, angiostenosis (e.g., after percutaneous arterioplasty), distal angiopathy, cerebral apoplexy, chronic
30 reversible obstructions (e.g., bronchitis, asthma (chronic asthma, allergic asthma)), autoimmune disease, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders (e.g., hypersensitive enteropathy syndrome, etc.), impotence (e.g., organic impotence, psychic impotence, etc.), nephritis, cachexia (e.g.,
35 progressive weight loss due to the lipolysis, myolysis, anemia, edema,


anorexia, etc. associated with chronic diseases such as cancer, tuberculosis, endocrine disorder, AIDS, etc.), pancreatitis, or restenosis after PTCA.





wherein R_1 represents an aryl lower alkyl group, said aryl group may be substituted with one or more groups selected from the group consisting of a halogen atom, an aryl group, a heterocyclic group, an aryl lower alkyl group, an aryl lower alkenyl group, a halo-lower alkyl group, a lower cycloalkyl-lower alkoxy group, a lower cycloalkoxy-lower alkyl group, an aryl lower alkynyl group, an aryloxy lower alkyl group, an aryl lower alkoxy group, a lower alkylthio group, a lower alkoxy group, and an alkenyl group; and R_2 represents a lower alkyl group, a lower alkenyl group, an aryl group, or a heterocyclic group, each of which may be substituted with a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an aryl group.

20 In the above formula (I), the aryl lower alkyl group presented by R_1 is preferably a halo-aryl lower alkyl group, wherein said aryl group may be substituted with a halo-lower alkyl group, a lower cycloalkyl lower alkoxy group, a lower cycloalkoxy lower alkyl group, an aryl lower alkynyl group, an aryloxy lower alkyl group, a lower alkylthio group, a lower alkoxy group, or a lower alkenyl group.

25 The indole derivatives provided by the present invention can be prepared according to the following formulae (a) to (c).











wherein R_1 and R_2 have the same meanings as described above, and R_3 is a lower alkyl group.


Compound (2) can be converted into compound (3) by reacting it with a haloid of R_1 in the presence of silver oxide. Compound (3) can also be obtained by reacting compound (2) with a haloid of R_1 in the presence of tartaric acid and a base such as sodium hydroxide, etc. Further, compound (2) can be converted into compound (3) by reacting it with silanes represented by triethylsilane and aldehydes corresponding to R_1 . Compound (4) can be produced by hydrolyzing compound (3) with a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc. Compound (1) can be produced by treating compound (4) with a carboxyl group-activating agent represented by carbonyldiimidazole, 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide or a salt thereof, dicyclohexylcarbodiimide, isobutyloxycarbonyl chloride, isobutyloyl chloride, pivaloyl chloride, etc., followed by reacting the product with sulfonamide in the presence of a base.

When R_1 in compounds (3), (4), and (1) is an aryl lower-alkyl group, which is substituted by an alkenyl group or an aryl alkenyl group, it is possible to convert the compounds into compounds of which R_1 is an aryl lower-alkyl group, which is substituted by an alkyl group or an aryl alkyl group, by hydrogenating them in the presence of a transition-metal catalyst such as platinum dioxide. Further, when R_1 is an aryl lower-alkyl group, which is substituted by an alkynyl group or an aryl alkynyl group, it is possible to convert the compounds into compounds of which R_1 is an aryl lower-alkyl group, which is

substituted by an alkenyl group, an aryl lower-alkenyl group, an alkyl group, or an aryl lower-alkyl group by hydrogenating them in the presence of a transition-metal catalyst such as platinum dioxide.

The indole derivatives of this invention can also be produced according to the following formulae (d) to (j):





wherein each of R_1 , R_2 , or R_3 has the same meanings as indicated above; R_1' , a halo-aryl lower-alkyl group; and Z , a halogen atom.

Compound (2) can be converted into compound (5) according to formula (d) that is similar to formula (a). Compound (5) can be converted into compound (6) according to formula (e) that is similar to formula (b), and compound (6) can be converted into compound (7) according to formula (f) that is similar to formula (c). Substituent R_1' of compound (5), (6), or (7) can be converted into the above-mentioned substituent R_1 . For example, when each of compound (5), (6), and (7) is reacted to aryl borate, thienyl borate, furyl borate, alkene, arylalkene, alkyne or arylalkyne in the presence of a palladium catalyst, the compound can be converted into a compound with an aryl lower-alkyl group, which is equivalent to compound (3), (4), or (1) of which R_1 is substituted by an aryl group, a thienyl group, a furyl group, an alkenyl group, an aryl alkenyl group, an alkynyl group, or an aryl alkynyl group.

Further, compound (4) can be converted into compound (8) by using a halogenating agent such as thionyl chloride, thionyl bromide, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, oxalyl chloride, or phosphorus tribromide (formula (g)). In the formula, Z is a halogen atom, preferably, a bromine atom or a chlorine atom. Compound (1) can be synthesized from compound (8) and sulfonamide in the presence or absence of a base (formula (h)). Compound (9) can be synthesized from compound (8) and ammonia or aqueous ammonia (formula (i)). Compound (1) can be synthesized from compound (9) and sulfonyl halide in the presence or absence of a base (formula (j)).

If desired, the intermediates formed in the above-mentioned steps may optionally be purified, prior to being subjected to the next step, through any conventional purification including, for

example, recrystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography and the like. If also desired, the final products of the compounds of the present invention may optionally be purified through any conventional
5 purification which is employed in the art of purifying organic compounds and which includes, for example, recrystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography and the like. To identify these compounds, employable is any of NMR spectrography, mass spectrography, IR
10 spectrography, elementary analysis, measurement of melting point and others.

Preferred Examples and their details of various definitions as referred to herein to be within the scope of the present invention are described below.

15 The lower alkyl group used herein preferably has 1 to 6 carbon atoms, including a linear or branched alkyl group such as a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, an i-butyl group, a sec-butyl group, a t-butyl group, an n-pentyl group, an i-pentyl group, a sec-pentyl group, a t-pentyl
20 group, a 2-methylbutyl group, an n-hexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 4-methylpentyl group, a 1-ethylbutyl group, a 2-ethylbutyl group, a 1,1-dimethylbutyl group, a 2,2-dimethyl-butyl group, a 3,3-dimethylbutyl group, a 1-ethyl-1-methylpropyl group, an n-hexyl
25 group, etc.

The alkenyl group used herein includes a lower alkenyl group having 2 to 6 carbon atoms and a higher alkenyl group having 7 to 20 carbon atoms, and examples thereof include a linear or branched alkenyl group, such as a vinyl group, an ethenyl group, a 1-propenyl
30 group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1,3-butadienyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 1,4-methylpentenyl group, a 1-heptenyl group, a
35 1-octenyl group, a 1-nonenyl group, a 1-decenyl group, a 1-undecenyl

group, a 1-dodecenyl group, a 1-tridecenyl group, a 1-tetradecenyl group, a 1-pentadecenyl group, a 1-hexadecenyl group, a 1-octadecenyl group, etc. Preferably, those having 2 to 8 carbon atoms are used.

5 The lower alkenyl group preferably includes vinyl, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1,4-methylpentenyl, etc.

10 The aryl group means those having 6 to 10 carbon atoms such as phenyl, naphthyl, and such. When simply referred to as "naphthyl group", it includes 1-naphthyl and 2-naphthyl groups.

15 The aryl lower alkyl group means the lower alkyl group described above to which the above-described aryl group is bonded, including benzyl, 1-phenylethyl, 2-phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, naphthylpentyl, naphthylhexyl, etc.

The halogen atom includes fluorine, chlorine, bromine, and iodine atoms.

20 The heterocyclic group means an unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero atom such as oxygen, sulfur, and nitrogen atoms, including furanyl, thiophenyl, pyrrolyl, imidazolyl, furyl, thienyl, thiazolyl, pyridyl, benzimidazolyl, benzofuryl, indolyl, benzothienyl, quinolyl, isoquinolyl, etc. The position of the substituted hetero atom
25 described above on the aromatic ring is not particularly restricted.

The aryl lower alkenyl group means the above-described lower alkenyl group to which the above-described aromatic group is bonded, including 1-phenylethenyl, 2-phenylethenyl, 1-phenyl-1-propenyl, 2-phenyl-1-propenyl, 3-phenyl-1-propenyl, 1-phenyl-2-propenyl, 2-phenyl-2-propenyl, 3-phenyl-2-propenyl, 1-phenyl-1-butenyl, 2-phenyl-1-butenyl, 4-phenyl-2-butenyl, 3-phenyl-2-propenyl, 2-phenyl-1-pentenyl, 2-phenyl-3-pentenyl, 2-phenyl-1-pentenyl, 2-phenyl-1-hexenyl, etc.

35 The halo-lower alkyl group means the above-described lower alkyl group substituted with the above-described halogen atom, including

fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, iodomethyl, 1-fluoroethyl, 1-chloromethyl, 1-bromomethyl, 2-fluoroethyl, 2-chloromethyl, 2-bromomethyl, 1,1-difluoroethyl, 1,1-dichloroethyl, 1,1-dibromoethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2-dibromoethyl, 1,2-difluoroethyl, 1,2-dichloroethyl, 1,2-dibromoethyl, 2,2,2-trifluoroethyl, heptafluoroethyl, 1-fluoropropyl, 1-chloropropyl, 1-bromopropyl, 2-fluoropropyl, 2-chloropropyl, 2-bromopropyl, 3-fluoropropyl, 3-chloropropyl, 3-bromopropyl, 1,1-difluoropropyl, 1,1-dichloropropyl, 1,1-dibromopropyl, 1,2-difluoropropyl, 1,2-dichloropropyl, 1,2-dibromopropyl, 2,3-difluoropropyl, 2,3-dichloropropyl, 2,3-dibromopropyl, 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, 2-fluorobutyl, 2-chlorobutyl, 2-bromobutyl, 4-fluorobutyl, 4-chlorobutyl, 4-bromobutyl, 4-iodobutyl, 3,4-dichlorobutyl, 2,4-dibromopentyl, 4,4,4-pentafluorobutyl, 2,2,3,3,4,4,4-heptafluorobutyl, perfluorobutyl, 2-fluoropentyl, 2-chloropentyl, 2-bromopentyl, 5-fluoropentyl, 5-chloropentyl, 3-iodopentyl, 5-bromopentyl, 2-fluorohexyl, 2-chlorohexyl, 2-bromohexyl, 6-fluorohexyl, 6-chlorohexyl, 6-bromohexyl, 1,3,5-trifluorohexyl, perfluorohexyl, etc.

The lower alkoxy group means a straight or branched alkoxyl group having up to 6 carbon atoms, including methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, sec-butyloxy, t-butyloxy, n-pentyloxy, i-pentyloxy, sec-pentyloxy, 2,2-dimethylpropyloxy, 2-methylbutoxy, n-hexyloxy, i-hexyloxy, t-hexyloxy, sec-hexyloxy, 2-methylpentyloxy, 3-methylpentyloxy, 1-ethylbutyloxy, 2-ethylbutyloxy, 1,1-dimethylbutyloxy, 2,2-dimethylbutyloxy, 3,3-dimethylbutyloxy, 1-ethyl-1-methylpropyloxy, etc.

The lower cycloalkyl-lower alkoxy group means the above-described lower alkoxy group to which a cycloalkyl group having 3 to 7 carbon atoms is bonded. Such a cycloalkyl group includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and such. Examples of the lower cycloalkyl-lower alkoxy group include (cyclopropylmethyl)oxy, (2-cyclopropylethyl)oxy, (cyclobutyl-

methyl)oxy, (3-cyclobutylpropyl)oxy, (cyclopentylmethyl)oxy, (2-cyclopentylethyl)oxy, (4-cyclopentylbutyl)oxy, (cyclohexylmethyl)oxy, (1-cyclohexylethyl)oxy, (2-cyclohexylethyl)oxy, (3-cyclohexylpropyl)oxy, (2-cyclohexylpropyl)oxy, (1-cyclohexylpropyl)oxy, (4-cyclohexylbutyl)oxy, (3-cyclohexylbutyl)oxy, (2-cyclohexylbutyl)oxy, (6-cyclohexylhexyl)oxy, (1-cyclohexylbutyl)oxy, cycloheptylmethyloxy, etc.

The lower cycloalkoxy-lower alkyl group means the above-described lower alkyl group having bonded thereto a cycloalkoxy group having 3 to 7 carbon atoms, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and such. Examples thereof include (cyclopropyloxy)methyl, 2-(cyclopropyloxy)ethyl, (cyclobutyloxy)methyl, 3-(cyclobutyloxy)propyl, cyclopentyl-oxymethyl, 2-(cyclopentyloxy)ethyl, 4-(cyclopentyloxy)butyl, (cyclohexyloxy)methyl, 1-(cyclohexyloxy)ethyl, 2-(cyclohexyloxy)ethyl, 3-(cyclohexyloxy)propyl, 2-(cyclohexyloxy)propyl, 1-(cyclohexyloxy)propyl, 4-(cyclohexyloxy)butyl, 3-(cyclohexyloxy)butyl, 2-(cyclohexyloxy)butyl, 6-(cyclohexyloxy)hexyl, 1-(cyclohexyloxy)butyl, (cycloheptyloxy)methyl, etc.

The aryl lower alkynyl group means an alkynyl group having 2 to 6 carbon atoms to which the above-described aryl group is bonded, including phenylethynyl, 3-phenyl-1-propynyl, 3-phenyl-1-butylnyl, 4-phenyl-1-butylnyl, 4-phenyl-2-butylnyl, 1-phenyl-2-pentylnyl, 1-phenyl-4-pentylnyl, 6-phenyl-1-hexynyl, etc.

The aryloxy lower alkyl group means the above-described aryl group to which the above-described lower alkyl group is bonded via an oxygen atom, including (phenyloxy)methyl, (1-naphthyloxy)methyl, (2-naphthyloxy)methyl, 1-(phenyloxy)ethyl, 2-(phenyloxy)ethyl, 1-(1-naphthyloxy)ethyl, 1-(2-naphthyloxy)ethyl, 2-(1-naphthyloxy)ethyl, 2-(2-naphthyloxy)ethyl, 1-(phenyloxy)propyl, 2-(phenyloxy)propyl, 3-(phenyloxy)propyl, 1-(1-naphthyloxy)propyl, 1-(2-naphthyloxy)propyl, 2-(1-naphthyloxy)propyl, 2-(2-naphthyloxy)propyl, 3-(1-naphthyloxy)propyl, 3-(2-naphthyloxy)propyl, 4-(phenyloxy)butyl, 5-(phenyloxy)pentyl, 6-

(phenyloxy)hexyl, etc.

The aryl lower alkoxy group means the above-described aryl group to which the above-described lower alkoxy group is bonded, including benzyloxy, 1-naphthylmethoxy, 2-naphthylmethoxy, (1-phenylethyl)oxy, (2-phenylethyl)oxy, (1-naphthylethan-1-yl)oxy, (2-naphthylethan-1-yl)oxy, (1-naphthylethan-2-yl)oxy, (2-naphthylethan-2-yl)oxy, (1-phenylpropyl)oxy, (2-phenylpropyl)oxy, (3-phenylpropyl)oxy, (1-naphthylpropan-1-yl)oxy, (2-naphthylpropan-1-yl)oxy, (1-naphthylpropan-2-yl)oxy, (2-naphthylpropan-2-yl)oxy, (1-naphthylpropan-3-yl)oxy, (2-naphthylpropan-3-yl)oxy, (4-phenylbutyl)oxy, (2-naphthylbutan-4-yl)oxy, (5-phenylpentyl)oxy, (2-naphthylpentan-5-yl)oxy, (6-phenylhexyl)oxy, (1-naphthylhexan-6-yl)oxy, etc.

The lower alkylthio group means a straight or branched alkylthio group having up to 6 carbon atoms, including methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio, sec-butylthio, t-butylthio, n-pentylthio, i-pentylthio, sec-pentylthio, t-dimethylpropylthio, 2-methylbutylthio, n-hexylthio, i-hexylthio, t-hexylthio, sec-hexylthio, 2-methylpentylthio, 3-methylpentylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1-dimethylbutylthio, 2,2-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethyl-1-methylpropylthio, etc. Preferred are those having carbon atoms 1 to 4 such as methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio, sec-butylthio, t-butylthio, and such.

The halo-aryl group means the above-described aryl group substituted with the above-described halogen atom, including 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 2-iodophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 3-iodophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-iodophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2,6-dichlorophenyl, 4-bromo-2-chlorophenyl, 1-bromonaphthalen-2-yl, 2-chloronaphthalen-1-yl, 5-chloronaphthalen-1-yl, 6-chloronaphthalen-1-yl, 4-chloroisoquinolin-8-yl, 2-chloroquinolin-4-yl, 4-bromoisoquinolin-1-yl, 5-chlorothiophen-2-yl, 5-bromothiophen-2-yl, 5-chlorothiophen-3-yl, etc.

Preferred salts of the indole derivatives of the present invention are non-toxic, ordinary pharmaceutically acceptable salts thereof. For example, mentioned are salts of the derivatives with bases as well as acid-addition salts of the derivatives, which include, for example, salts thereof with inorganic bases, such as salts with alkali metals (e.g., sodium, potassium); salts with alkaline earth metals (e.g., calcium, magnesium); ammonium salts; salts with organic amines (e.g., triethylamine, pyridine, picoline, ethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine); salts with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid); salts with organic carboxylic acids (e.g., formic acid, acetic acid, trifluoroacetic acid, maleic acid, tartaric acid); salts with sulfonic acids (e.g., methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid); salts with basic or acidic amino acids (e.g., arginine, aspartic acid, glutamic acid), etc.

The compounds of the invention could contain one or more chiral centers, therefore they could be enantiomers or diastereomers. Few of the compounds containing alkenyl group could also be cis- or trans-isomers. In both cases, each of such isomers as well as the mixture thereof are within the scope of this invention.

The compounds of the invention can also exist as tautomers, and individual of such tautomers and the mixture thereof are within the scope of this invention.

The compounds of the invention and their salts can be solvate, which are also within the invention. The solvent for the solvate is preferably hydrate or ethanol.

Specific examples of the inventive compound are 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(4-methylbenzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-iodobenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-chloro-4-iodobenzyl)-2-methyl-5-((4-methyl-benzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-chloro-4-(phenyl-

ethynyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyle)-
indole, 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-((4-
methylbenzene)sulfonylcarbamoyle)indole, 3-(2-chloro-4-(2-phenyl-
ethenyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyle)indole,
5 3-(2-chloro-4-(2-phenylethyl)benzyl)-2-methyl-5-((4-methyl-
benzene)sulfonylcarbamoyle)indole, 3-(2-chloro-4-(benzyloxy)-
benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyle)indole,
3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methyl-5-((4-
methylbenzene)sulfonylcarbamoyle)indole, 3-(2-chloro-4-phenyl-
10 benzyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyle)-2-methyl-
indole, 3-(2-chloro-4-phenylbenzyl)-5-((5-bromo-2-thiophene-
sulfonyl)carbamoyle)-2-methylindole, 3-(2-chloro-4-phenylbenzyl)-
2-methyl-5-(4-pentenesulfonylcarbamoyle)indole, 3-((1-bromo-
naphthalen-2-yl)methyl)-5-((5-chloro-2-thiophenesulfonyl)-
15 carbamoyle)-2-methylindole, 3-((1-bromonaphthalen-2-yl)methyl)-5-
((5-bromo-2-thiophenesulfonyl)carbamoyle)-2-methylindole, 3-(4-
bromo-2-chlorobenzyl)-2-methyl-5-((4-methylbenzene)sulfonyl-
carbamoyle)indole, 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-
vinylbenzene)sulfonylcarbamoyle)indole, 3-(4-bromo-2-chloro-
20 benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyle)indole,
3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((1-pentene)sulfonyl-
carbamoyle)indole, 3-(4-bromo-2-chlorobenzyl)-5-((5-bromo-2-
thiophenesulfonyl)carbamoyle)-2-methylindole, 3-(4-bromo-2-
chlorobenzyl)-2-methyl-5-(4-pentenesulfonylcarbamoyle)indole, 5-
25 ((5-chloro-2-thiophenesulfonyl)carbamoyle)-3-(2,4-dichloro-
benzyl)-2-methylindole, 5-((5-bromo-2-thiophenesulfonyl)-
carbamoyle)-3-(2,4-dichlorobenzyl)-2-methylindole, 3-(2-chloro-4-
(trifluoromethyl)benzyl)-2-methyl-5-(1-pentanesulfonyl-
carbamoyle)indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-
30 methyl-5-(4-methylbenzenesulfonylcarbamoyle)indole, 3-(2-chloro-
4-(trifluoromethyl)benzyl)-2-methyl-5-((5-chloro-2-thiophene-
sulfonyl)carbamoyle)indole, 3-(2-chloro-4-(trifluoromethyl)-
benzyl)-2-methyl-5-((5-bromo-2-thiophenesulfonyl)carbamoyle)-
indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((4-
35 vinylbenzene)sulfonylcarbamoyle)indole, 3-(2-chloro-4-(trifluoro-

methyl)benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)-
 indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((1-
 pentene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(phenoxymethyl)-
 benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 5 chloro-4-(phenoxymethyl)benzyl)-2-methyl-5-(4-methylbenzene-
 sulfonylcarbamoyl)indole, 3-(2-chloro-4-(cyclohexyloxymethyl)-
 benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(4-methyl-
 benzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-ethoxybenzyl)-2-
 10 methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-
 4-ethoxybenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole,
 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-(4-methyl-
 benzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(thiophen-2-
 yl-)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 15 chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonyl-
 carbamoyl)indole, 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-
 (4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(1-
 hexen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonyl-
 carbamoyl)indole, 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-
 20 (4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(1-
 hexen-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole,
 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(1-pentane-
 sulfonylcarbamoyl)indole, etc.

The indole derivatives and their pharmaceutically acceptable
 25 salts of the present invention that are mentioned hereinabove are
 effective for preventing and treating various disorders, for example,
 impaired glucose tolerance, diabetes (type II diabetes), diabetic
 complications (e.g., diabetic nephropathy, diabetic neuropathy,
 diabetic retinopathy, etc.), syndrome of insulin resistance (e.g.,
 30 insulin receptor disorders, Rabson-Mendenhall syndrome,
 leprechaunism, Kobberling-Dunnigan syndrome, Seip syndrome,
 Lawrence syndrome, Cushing syndrome, acromegaly, etc.), polycystic
 ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular
 disorders (e.g., stenocardia, cardiac failure, etc.), hyperglycemia
 35 (e.g., abnormal saccharometabolism such as feeding disorders, etc.),

and hypertension based on their blood sugar level-depressing activity, as well as stenocardia, hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy (e.g., diabetic glomerulosclerosis, etc.), tubulointerstitial disorders (e.g.,
5 renopathy induced by FK506, cyclosporin, etc.), renal failure, atherosclerosis, angiostenosis (e.g., after percutaneous arterioplasty), distal angiopathy, cerebral apoplexy, chronic reversible obstructions (e.g., bronchitis, asthma (chronic asthma, allergic asthma), etc.), autoimmune diseases, allergic rhinitis,
10 urticaria, glaucoma, diseases characterized by enteromotility disorders (e.g., hypersensitive enteropathy syndrome, etc.), impotence (e.g., organic impotence, psychic impotence, etc.), diabetic complications (e.g., diabetic gangrene, diabetic arthropathy, diabetic glomerulosclerosis, diabetic dermatopathy,
15 diabetic neuropathy, diabetic cataract, diabetic retinopathy, etc.), nephritis, cachexia (e.g., progressive weight loss due to the lipolysis, myolysis, anemia, edema, anorexia, etc. associated with chronic diseases such as cancer, tuberculosis, endocrine disorder, AIDS, etc.), pancreatitis, and restenosis after PTCA based on their
20 cGMP-PDE (especially PDE5)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

To use the indole derivatives of the present invention for treating diseases or disorders such as those mentioned hereinabove,
25 they may be formulated into pharmaceutical compositions of ordinary forms, which comprise, as an active ingredient, any of the derivatives along with pharmaceutically acceptable carriers, such as organic or inorganic solid or liquid vehicles, and which are suitable for oral administration, parenteral administration, or external application.
30 The pharmaceutical compositions may be of any solid form of tablets, granules, powders, capsules, etc., or may be of any liquid form of solutions, suspensions, syrups, emulsions, lemonades, etc.

If desired, the pharmaceutical compositions may further contain a pharmaceutical aid, a stabilizer, a wetting agent, and also any
35 ordinary additive of, for example, lactose, citric acid, tartaric

acid, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, etc.

5 The amount of the above-mentioned derivative of the present invention to be used shall vary, depending on the age and the condition of patients, the type and the condition of diseases or disorders, and the type of the derivative to be used. In general, for oral administration, the dose of the derivative may be from 1 to 100 mg/kg; and for intramuscular injection or intravenous injection, it may be 10 from 0.1 to 10 mg/kg. Such a unit dose may be applied to a patient once to four times a day.

BRIEF DESCRIPTION OF THE DRAWINGS

- 15 Fig. 1 shows chemical formulae of compound (9) to compound (11).
Fig. 2 shows chemical formulae of compound (12) to compound (14).
Fig. 3 shows chemical formulae of compound (15) to compound (17).
Fig. 4 shows chemical formulae of compound (18) to compound (20).
Fig. 5 shows chemical formulae of compound (21) to compound (23).
Fig. 6 shows chemical formulae of compound (24) to compound (26).
20 Fig. 7 shows chemical formulae of compound (27) to compound (29).
Fig. 8 shows chemical formulae of compound (30) to compound (32).
Fig. 9 shows chemical formulae of compound (33) to compound (35).
Fig. 10 shows chemical formulae of compound (36) to compound (38).
25 Fig. 11 shows chemical formulae of compound (39) to compound (41).
Fig. 12 shows chemical formulae of compound (42) to compound (44).
Fig. 13 shows chemical formulae of compound (45) to compound (47).
30 Fig. 14 shows chemical formulae of compound (48) to compound (50).
Fig. 15 shows chemical formula of compound (51).

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is illustrated more specifically by referring to the Examples below. However, the present invention is not limited thereto.

5

Production Example 1

Production of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 5-(methoxycarbonyl)-2-methylindole (6.62 g),
10 2-chloro-4-iodobenzyl bromide (32.0 g), L-tartaric acid (12.44 g), sodium hydroxide (3.32 g), 1,4-dioxane (100 ml) and water (55 ml) was stirred at 95°C for 55 hours. The mixture was cooled down to room temperature and then a precipitated solid material was separated by filtration. The solid material was washed with water, with hexane,
15 and then with isopropanol, and dried to give 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (7.27 g).

¹H-NMR (CDCl₃, δ ppm): 2.35(3H, s), 3.89(3H, s), 4.09(2H, s), 6.63(1H, d, J=8.2Hz), 7.30(1H, d, J=8.6Hz), 7.36(1H, d, J=8.2Hz), 7.73(1H, d, J=1.4Hz), 7.85(1H, d, J=8.5Hz), 8.07(1H, brs), 8.08(1H, s)

20

Production of 5-carboxy-3-(2-chloro-4-iodobenzyl)-2-methylindole (step 2)

A mixture of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g), a 10% aqueous solution of sodium hydroxide
25 (5 ml), and ethanol (5 ml) was heat-refluxed for 1 hour. The reaction solution was cooled down and then the pH was adjusted to 6 with 1N hydrochloric acid. A precipitated solid material was collected, washed with water and then with a mixed solution of water and ethanol, and dried to yield white crystals of 5-carboxy-3-(2-chloro-4-iodobenzyl)-2-methylindole (0.640 g).
30

¹H-NMR (DMSO-d₆, δ ppm): 2.32(3H, s), 4.04(2H, s), 6.75(1H, d, J=8.2Hz), 7.30(1H, d, J=8.5Hz), 7.52(1H, d, J=8.1Hz), 7.62(1H, d, J=8.4Hz), 7.80(1H, s), 7.87(1H, s), 11.27(1H, s), 12.28(1H, brs)

35 Production Example 2

Production of 3-(2-chloro-4-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (0.88 g), phenylacetylene (1.02 g),
5 palladium (II) acetate (0.090 g), triphenylphosphine (0.21 g), tri-n-butylamine (0.75 g), copper (I) iodide (0.12 g) and N,N-dimethylformamide (15 ml) was stirred at 60°C overnight. The solvent was distilled off under reduced pressure, and a mixed solution of ethanol and water was added thereto. The resulting insoluble
10 material was separated by filtration and dried to obtain 3-(2-chloro-4-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g).

¹H-NMR (CDCl₃, δ ppm): 2.36(3H, s), 3.89(3H, s), 4.17(2H, s), 6.89(1H, d, J=7.5Hz), 7.21(1H, dd, J=8.0 and 1.7Hz), 7.24-7.53(5H, m), 7.58(1H, d, J=1.7Hz), 7.68-7.71(1H, m), 7.85(1H, dd, J=8.6 and 1.6Hz), 8.07(1H, brs), 8.12(1H, s)

Production of 5-carboxy-3-(2-chloro-4-phenylethenyl)benzyl)-2-methylindole (step 2)

20 According to the method used in step 2 of Production Example 1, 5-carboxy-3-(2-chloro-4-phenylethenyl)benzyl)-2-methylindole (0.75 g) was obtained from 3-(2-chloro-4-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.34(3H, s), 4.12(2H, s), 7.02(1H, d, J=7.8Hz), 7.20-7.70(1H, m), 7.85-7.95(1H, m), 11.27(1H, s), 12.24(1H, brs)

Production Example 3

Production of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (1.32 g), styrene (1.57 g), palladium (II) acetate (0.090 g), triphenylphosphine (0.21 g), tri-n-butylamine (1.10 g), and N,N-dimethylformamide (25 ml) was stirred at 60°C
35 overnight. The solvent was distilled off under reduced pressure, and

a mixed solution of ethanol and water was added thereto. The resulting insoluble material was separated by filtration and dried to obtain 3-(2-chloro-4-(2-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g).

5 ¹H-NMR (CDCl₃, δ ppm): 2.35 and 2.38(3H, 2s), 3.88(3H, s), 4.17(2H, s), 6.90-8.17(13H, m)

Production of 5-carboxy-3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylindole (step 2)

10 According to the method used in step 2 of Production Example 1, 5-carboxy-3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylindole (0.83 g) was obtained from 3-(2-chloro-4-(2-phenylethenyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g).

15 ¹H-NMR (DMSO-d₆, δ ppm): 2.33 and 2.35(3H, 2s), 4.09(2H, s), 6.98-7.92(13H, m), 11.22(1H, s)

Production Example 4

20 Production of 3-(2-chloro-4-t-butylthiobenzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (0.498 g), tetrakis triphenylphosphine palladium (0) (0.262 g), tri-n-butylamine (0.420 g), t-butylmercaptan (0.510 g), and N,N-dimethylformamide (5 ml) was
25 stirred at 60°C overnight. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluate: hexane/ethyl acetate = 2/1) to give 3-(2-chloro-4-(t-butylthio)benzyl)-5-(methoxycarbonyl)-2-methylindole (0.360 g).

30 ¹H-NMR (CDCl₃, δ ppm): 1.55(9H, s), 2.36(3H, s), 3.88(3H, s), 4.16(2H, s), 6.87(1H, d), 7.20-7.33(2H, m), 7.58(1H, s), 7.86(1H, d), 8.06(1H, brs), 8.12(1H, s)

35 Production of 5-carboxy-3-(2-chloro-4-(t-butylthio)benzyl)-2-methylindole (step 2)

10 $^1\text{H-NMR}$ (DMSO-d_6 , δ ppm): 1.20(9H, s), 2.33(3H, s), 4.12(2H, s), 7.02(1H, d, $J=7.9\text{Hz}$), 7.30(2H, m), 7.52(1H, s), 7.62(1H, d, $J=8.4\text{Hz}$), 11.27(1H, brs)

Production Example 5

15 Production of 5-carboxy-3-(2-chloro-4-(benzyloxy)benzyl)-2-methylindole (steps 1 and 2)

A mixture of 5-(methoxycarbonyl)-2-methylindole (0.380 g), 2-chloro-4-benzyloxybenzyl chloride (1.068 g), L-tartaric acid (0.750 g), sodium hydroxide (0.200 g), sodium iodide (0.15 g), 1,4-dioxane (6 ml), and water (3 ml) was stirred at 95°C for 46 hours. The reaction solution was concentrated and then subjected to extraction with ethyl acetate, followed by successive washing with water, 1N hydrochloric acid, and a 10% aqueous solution of sodium hydroxide. The separated ethyl-acetate layer was concentrated. Ethanol (7 ml) and a 10% aqueous solution of sodium hydroxide (5 ml) were added to the residual material containing 3-(2-chloro-4-(benzyloxy)benzyl)-5-(methoxycarbonyl)-2-methylindole, and the mixture was heat-refluxed for 1 hour. The reaction solution was cooled down to room temperature and then the pH was adjusted to about 5 with 1N hydrochloric acid. The solution was subjected to extraction with ethyl acetate and washed with water. The separated ethyl-acetate layer was concentrated to yield oily material (0.41 g) containing 5-carboxy-3-(2-chloro-4-(benzyloxy)benzyl)-2-methylindole.

35 $^1\text{H-NMR}$ (DMSO-d_6 , δ ppm): 2.32(3H, s), 4.01(2H, s), 5.05(2H, s),

6.84(1H, dd, J=8.6 and 2.6Hz), 7.11(1H, d, J=7.5Hz), 7.27-7.44(6H, m), 7.61(1H, d, J=8.6Hz), 7.89(1H, s), 11.22(1H, s)

Production Example 6

- 5 Production of 3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 5-(methoxycarbonyl)-2-methylindole (0.170 g), 2-chloro-4-(cyclohexylmethyloxy)benzyl chloride (0.49 g), L-tartaric acid (0.300 g), sodium hydroxide (0.080 g), sodium iodide
10 (0.075 g), 1,4-dioxane (3 ml), and water (1.5 ml) was stirred at 80°C for 40 hours. The reaction solution was concentrated and then subjected to extraction with ethyl acetate, followed by successive washing with water, 1N hydrochloric acid, and a 10% aqueous solution of sodium hydroxide. The separated ethyl-acetate layer was
15 concentrated, and the residual material was washed with water and then with ethanol to obtain white crystals (0.23 g) of 3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-5-(methoxycarbonyl)-2-methylindole.

¹H-NMR (CDCl₃, δ ppm): 0.97-1.06(2H, m), 1.14-1.33(3H, m), 1.66-
20 1.86(6H, m), 2.36(3H, s), 3.68(2H, d, J=6.4Hz), 3.89(3H, s), 4.09(2H, s), 6.60(1H, dd, J=8.6 and 2.5Hz), 6.81(1H, d, J=8.5Hz), 6.94(1H, d, J=2.5Hz), 7.29(1H, d, J=8.4Hz), 7.84(1H, dd, J=8.4 and 1.4Hz), 8.00(1H, s), 8.14(1H, s)

- 25 Production of 5-carboxy-3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methylindole (step 2)

Ethanol (10 ml) and a 10% aqueous solution of sodium hydroxide (5 ml) were mixed with 3-(2-chloro-4-(cyclohexylmethyloxy)-benzyl)-5-(methoxycarbonyl)-2-methylindole (0.220 g), and the
30 mixture was heat-refluxed for 1.5 hours. The reaction solution was cooled down to room temperature, the pH was adjusted to about 6 by using 1N hydrochloric acid, and then the resulting precipitate was collected by filtration. The precipitate was washed with water and with 2-propanol and subsequently dried to give white crystals (0.190
35 g) of 5-carboxy-3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-

methylindole.

¹H-NMR (DMSO-d₆, δ ppm): 0.94-1.03(2H, m), 1.09-1.26(3H, m), 1.58-1.78(6H, m), 2.32(3H, s), 3.72(2H, d, J=6.4Hz), 3.99(2H, s), 6.73(1H, dd, J=8.7 and 2.6Hz), 6.85(1H, d, J=8.6Hz), 6.99(1H, d, J=2.6Hz), 7.23(1H, d, J=8.4Hz), 7.61(1H, dd, J=8.4 and 1.5Hz), 7.86(1H, s), 11.12(1H, s)

Production Example 7

Production of 3-(2-chloro-4-(trifluoromethyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

Trifluoroacetic acid (11.0 g) and triethylsilane (22.4 g) were mixed in a mixed solvent of dichloromethane (10 ml) and acetonitrile (10 ml), and the mixture was cooled with ice. Thereto, a solution, which was prepared by dissolving 5-(methoxycarbonyl)-2-methylindole (6.07 g) and 2-chloro-4-(trifluoromethyl)benzaldehyde (8.04 g) in a mixed solvent of dichloromethane (30 ml) and acetonitrile (30 ml), was added dropwise over a period of 30 minutes. The mixture was stirred at room temperature for 4 hours, and then trifluoroacetic acid (66.0 g) was added thereto. The mixture was further stirred at room temperature for 17 hours. The reaction solution was cooled with ice, and then a 10% aqueous solution of sodium hydroxide (250 ml) was added slowly thereto. The solution was neutralized by adding 1N hydrochloric acid (40 ml) and the resulting solid material was collected by filtration. The filtrate was subjected to extraction with ethyl acetate (100 ml x 2). The extract was combined with the obtained solid material by filtration, and the solid was dissolved. The solution was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Hexane (200 ml) was added to the obtained concentrated oily residue and the mixture was stirred at room temperature. A precipitated solid material was collected by filtration. The material was purified by recrystallization from a mixed solvent of ethyl acetate (50 ml) and hexane (200 ml) to obtain pale pink crystals (8.83 g) of 3-(2-chloro-4-(trifluoromethyl)-benzyl)-5-(methoxycarbonyl)-2-methylindole.

¹H-NMR (DMSO-d₆, δ ppm): 2.34(3H, s), 3.76(3H, s), 4.19(2H, s),

7.16(1H, d, J=8.1Hz), 7.35(1H, d, J=8.5Hz), 7.56(1H, d, J=8.1Hz),
7.65(1H, d, J=8.5Hz), 7.86(1H, s), 7.90(1H, s), 11.39(1H, s)

5 Production of 3-carboxy-5-(2-chloro-4-(trifluoromethyl)benzyl)-
2-methylindole (step 2)

According to the method used in step 2 of Production Example
1, 3-carboxy-5-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-
indole (4.7 g) was obtained from 3-(2-chloro-4-(trifluoro-
methyl)benzyl)-5-(methoxycarbonyl)-2-methylindole (5.2 g).

10 ¹H-NMR (DMSO-d₆, δ ppm): 2.34(3H, s), 4.18(2H, s), 7.17(1H, d,
J=8.1Hz), 7.32(1H, d, J=8.3Hz), 7.56(1H, d, J=8.1Hz), 7.63(1H, d,
J=8.4Hz), 7.85(1H, s), 7.88(1H, s), 11.33(1H, s)

Production Example 8

15 Production of 3-(2-chloro-4-(phenoxyethyl)benzyl)-5-(methoxy-
carbonyl)-2-methylindole (step 1)

A mixture of 5-(methoxycarbonyl)-2-methylindole (0.568 g),
2-chloro-4-phenoxyethylbenzyl chloride (1.05 g), L-tartaric acid
(1.17 g), sodium hydroxide (0.312 g), sodium iodide (0.225 g),
20 1,4-dioxane (10 ml), and water (5 ml) was stirred at 80°C for two days.
After the mixture was cooled down to room temperature, water (50 ml)
and ethyl acetate (50 ml) were added thereto for separation. The
organic layer was dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The concentrated residue
25 obtained was purified by silica gel column chromatography (eluate:
methanol/chloroform = 2/98) to give a mixture (1.38 g) containing
the compound of interest. The mixture was used in the next step
without further purification.

30 Production of 5-carboxy-3-(2-chloro-4-(phenoxyethyl)benzyl)-2-
methylindole (step 2)

The mixture (0.634 g) containing 3-(2-chloro-4-
(phenoxyethyl)benzyl)-5-(methoxycarbonyl)-2-methylindole, which
was obtained by the above-mentioned method, was mixed with a 10%
35 aqueous solution of sodium hydroxide (4 ml) and ethanol (20 ml). The

resulting mixture was heat-refluxed for 3 hours. After the mixture was cooled down to room temperature, the pH was adjusted to about 5 by adding 1N hydrochloric acid (10 ml). Ethyl acetate (100 ml) heated to 40 to 50°C and water (100 ml) were added thereto for separation. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluate: methanol/chloroform = 5/95) to give 5-carboxy-3-(2-chloro-4-(phenoxyethyl)benzyl)-2-methylindole (0.380 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.35(3H, s), 4.10(2H, s), 5.03(2H, s), 6.93(1H, t, J=7.1Hz), 6.96-7.01(3H, m), 7.23-7.32(4H, m), 7.52(1H, s), 7.62(1H, d, J=8.5Hz), 7.91(1H, s), 11.26(1H, s), 12.26(1H, brs)

Production Example 9

Production of 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-5-methoxycarbonyl)-2-methylindole (step 1)

A mixture of 5-(methoxycarbonyl)-2-methylindole (0.568 g), 2-chloro-4-(cyclohexyloxymethyl)benzyl chloride (1.09 g), L-tartaric acid (1.17 g), sodium hydroxide (0.312 g), sodium iodide (0.225 g), 1,4-dioxane (10 ml), and water (5 ml) was stirred at 80°C for two days. After the mixture was cooled down to room temperature, water (50 ml) and ethyl acetate (50 ml) were added thereto for separation. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrated residue obtained was purified by silica gel column chromatography (eluate: methanol/chloroform = 2/98) and further purified by recrystallization from a mixed solvent of ethyl acetate (2 ml) and hexane (6 ml) to give a mixture (0.9 g) containing the compound of interest. The mixture was used in the next step without further purification.

Production of 5-carboxy-3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methylindole (step 2)

The mixture (0.9 g) containing 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-5-(methoxycarbonyl)-2-methylindole, which was

obtained by the above-mentioned method, was mixed with a 10% aqueous solution of sodium hydroxide (4 ml) and ethanol (20 ml). The resulting mixture was heat-refluxed for 3 hours. After the mixture was cooled down to room temperature, the pH was adjusted to about 4 by adding 1N hydrochloric acid (10 ml). Ethyl acetate (100 ml) heated to 40 to 50°C and water (100 ml) were added thereto for separation. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluate: methanol/chloroform = 5/95) to give a mixture (0.57 g) containing 5-carboxy-3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methylindole. The mixture was used in the next step without further purification.

Production Example 10

Production of 3-(2-chloro-4-ethoxybenzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

Trifluoroacetic acid (0.91 g) and triethylsilane (1.86 g) were mixed in dichloromethane (5 ml), and the mixture was cooled with ice. Thereto, a solution, which was prepared by dissolving 5-(methoxycarbonyl)-2-methylindole (0.50 g) and 2-chloro-4-ethoxybenzaldehyde (0.49 g) in a mixed solvent of dichloromethane (10 ml) and tetrahydrofuran (10 ml), was added dropwise over a period of 10 minutes. The mixture was stirred while being ice-cooled for 10 minutes, and then it was stirred at room temperature for 2 hours. Chloroform (5 ml) and hexane (30 ml) were added to the residue resulted from concentrating the reaction solution. The resulting precipitate was collected by filtration. Dichloromethane (10 ml), trifluoroacetic acid (0.91 g), and triethylsilane (1.86 g) were added to the precipitate, and the mixture was stirred at room temperature for 20 hours. The reaction solution was concentrated, purified by silica gel column chromatography (eluate: ethyl acetate/hexane = 1/3), and further purified by recrystallization from ethyl acetate/hexane to give 3-(2-chloro-4-ethoxybenzyl)-5-(methoxycarbonyl)-2-methylindole (0.52 g).

¹H-NMR (CDCl₃, δ ppm): 1.37(3H, t, J=6.9Hz), 2.35(3H, s), 3.88(3H, s), 3.97(2H, q, J=7.0Hz), 4.09(2H, s), 6.61(1H, d, J=2.5 and 8.5Hz), 6.82(1H, d, J=8.5Hz), 6.94(1H, d, J=2.5Hz), 7.29(1H, d, J=8.7Hz), 7.83(1H, dd, J=1.5 and 8.5Hz), 8.03(1H, brs), 8.19(1H, s)

5

Production of 5-carboxy-3-(2-chloro-4-ethoxybenzyl)-2-methylindole (step 2)

According to the method used in step 2 of Production Example 1, 5-carboxy-3-(2-chloro-4-ethoxybenzyl)-2-methylindole (0.382 g) was obtained from 3-(2-chloro-4-ethoxybenzyl)-5-(methoxycarbonyl)-2-methylindole (0.52 g).

10

¹H-NMR (DMSO-d₆, δ ppm): 1.27(3H, t, J=6.9Hz), 2.33(3H, s), 3.97(2H, q, J=7.0Hz), 4.01(2H, s), 6.74(1H, dd, J=2.5 and 8.6Hz), 6.88(1H, d, J=8.6Hz), 6.99(1H, d, J=2.5Hz), 7.29(1H, d, J=8.4Hz), 7.61(1H, d, J=8.4Hz), 7.89(1H, s), 11.22(1H, s), 12.25(1H, brs)

15

Production Example 11

Production of 3-(2-chloro-4-(thiophen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g), thiophene-2-boric acid (0.35 g), tetrakis triphenylphosphine palladium (0) (0.06 g), ethanol (1 ml), toluene (3 ml), and a 2M sodium carbonate aqueous solution (2.3 ml) was stirred at 90°C for 2 hours. The reaction solution was cooled down to room temperature, and toluene (50 ml) and water (50 ml) were added thereto for separation. The organic layer was filtered through anhydrous sodium sulfate and celite. The residue obtained by concentration under reduced pressure was recrystallized from ethanol/water (5 ml/5 ml) to yield 3-(2-chloro-4-(thiophen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (0.95 g).

20

25

30

¹H-NMR (DMSO-d₆, δ ppm): 2.36(3H, s), 3.76(3H, s), 4.11(2H, s), 7.01(1H, d, J=8.1Hz), 7.11(1H, t, J=4.3Hz), 7.34(1H, d, J=8.5Hz), 7.45(1H, d, J=8.1Hz), 7.53(2H, m), 7.64(1H, dd, J=1.3 and 8.5Hz), 7.73(1H, d, J=1.5Hz), 7.94(1H, s), 11.34(1H, s)

35

Production of 5-carboxy-3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methylindole (step 2)

According to the method used in step 2 of Production Example 1, 5-carboxy-3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methylindole (0.28 g) was obtained from 3-(2-chloro-4-(thiophen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (0.95 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.36(3H, s), 4.11(2H, s), 7.02(1H, d, J=8.2Hz), 7.11(1H, m), 7.31(1H, d, J=8.4Hz), 7.45(1H, dd, J=1.6 and 8.0Hz), 7.53(2H, m), 7.63(1H, dd, J=1.3 and 8.4Hz), 7.73(1H, d, J=1.5Hz), 7.93(1H, s), 11.27(1H, s), 12.26(1H, brs)

Production Example 12

Production of 3-(2-chloro-4-(furan-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (1.00 g), furan-2-boric acid (0.34 g), tetrakis triphenylphosphine palladium (0) (0.06 g), ethanol (1 ml), toluene (3 ml) and a 2M sodium carbonate aqueous solution (2.5 ml) was stirred at 90°C for 2.5 hours. The reaction solution was cooled down to room temperature, and toluene (50 ml) and water (50 ml) were added thereto for separation. The organic layer was filtered through celite. The resultant solution was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The obtained residue was recrystallized from ethanol/water (20 ml/20 ml) to yield 3-(2-chloro-4-(thiophen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (0.57 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.35(3H, s), 3.76(3H, s), 4.11(2H, s), 5.57(1H, dd, J=3.3 and 1.8Hz), 6.98(1H, d, J=3.3Hz), 7.04(1H, d, J=8.2Hz), 7.34(1H, d, J=8.5Hz), 7.49(1H, d, J=8.1Hz), 7.64(1H, d, J=8.5Hz), 7.73(1H, s), 7.76(1H, d, J=1.4Hz), 7.93(1H, s), 11.33(1H, s)

Production of 5-carboxy-3-(2-chloro-4-(furan-2-yl)benzyl)-2-methylindole (step 2)

According to the method used in step 2 of Production Example

1, 5-carboxy-3-(2-chloro-4-(furan-2-yl)benzyl)-2-methylindole (0.51 g) was obtained from 3-(2-chloro-4-(furan-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (0.57 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.36(3H, s), 4.11(2H, s), 6.57(1H, d, J=2.5Hz), 6.97(1H, d, J=3.1Hz), 7.05(1H, d, J=8.1Hz), 7.31(1H, d, J=8.5Hz), 7.49(1H, d, J=8.2Hz), 7.63(1H, d, J=8.4Hz), 7.72(1H, s), 7.76(1H, s), 7.92(1H, s), 11.26(1H, s), 12.26(1H, brs)

Production Example 13

10 Production of 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole (step 1)

A mixture of 3-(2-chloro-4-iodobenzyl)-5-(methoxycarbonyl)-2-methylindole (0.88 g), 1-hexene (0.84 g), palladium (II) acetate (0.068 g), triphenylphosphine (0.160 g), tri-n-butylamine (1.12 g), and N,N-dimethylformamide (15 ml) was stirred at 60°C for 5 hours. The reaction solution was concentrated under reduced pressure, and ethanol (10 ml) was added to the residue. An insoluble material was removed by filtration, and water (100 ml) and ethyl acetate (100 ml) were added to the solution for separation. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluate: ethyl acetate/hexane = 1/3) to give a mixture (0.29 g) of 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole and 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole. The mixture was used in the next step without further purification.

mp: 141-146°C

30 Production of 5-carboxy-3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methylindole (step 2)

According to the method used in step 2 of Production Example 1, a mixture (0.22 g) of 5-carboxy-3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methylindole and 5-carboxy-3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methylindole was obtained from a mixture (0.29 g) of

3-(2-chloro-4-(1-hexen-1-yl)benzyl)-5-methoxycarbonyl)-2-methylindole and 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-5-(methoxycarbonyl)-2-methylindole. The mixture was used in the next step without further purification.

5

Example 1

Synthesis of 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (9))

10 N,N'-carbonyldiimidazole (0.108 g) was added to a mixture of 5-carboxy-3-(2-chloro-4-(t-butylthio)benzyl)-2-methylindole (0.152 g) and N,N-dimethylformamide (2 ml), and then the resulting mixture was stirred at room temperature for 40 minutes. Subsequently, thereto, an N,N-dimethylformamide solution (2 ml) containing 1-pentanesulfonamide (0.095 g) and diazabicycloundecene (0.090 g) was
15 added, and the mixture was stirred at 100°C overnight. The solvent was distilled off under reduced pressure. Methanol and water were added to the residue, and the pH of the solution was adjusted to 3 by adding 1N hydrochloric acid thereto. The mixture was extracted twice with ethyl acetate. The organic layer was dried, concentrated,
20 and then purified by preparative thin layer chromatography (developing solvent: ethyl acetate/hexane = 1/1). Further, the material was recrystallized from a mixed solvent of methanol and water to obtain white crystals (0.103 g) of 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole.
25 ¹H-NMR (DMSO-d₆, δ ppm): 0.80(3H, t, J=7.3Hz), 1.20-1.38(13H, m), 1.66(2H, m), 2.29(3H, s), 3.47(2H, m), 4.13(2H, s), 6.96(1H, d, J=8.0Hz), 7.30(1H, d, J=7.9Hz), 7.35(1H, d, J=8.5Hz), 7.53(1H, s), 7.63(1H, d, J=8.5Hz), 8.05(1H, s), 11.38(1H, s), 11.67(1H, s)
mp: 185-187.5°C

30

Example 2

Synthesis of 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(4-methylbenzene)sulfonylcarbamoyl)indole (compound (10))

35 According to the method used in Example 1, a foamy solid material (0.155 g) of 5-((4-methylbenzene)sulfonylcarbamoyl)-3-

(2-chloro-4-(t-butylthio)benzyl)-2-methylindole was obtained from 5-carboxy-3-(2-chloro-4-t-butylthiobenzyl)-2-methylindole (0.120 g), N,N'-carbonyldiimidazole (0.085 g), (4-methylbenzene)-sulfonamide (0.079 g), and diazabicycloundecene (0.071 g).

- 5 ¹H-NMR (CDCl₃, δ ppm): 1.24(9H, s), 2.28(3H, s), 2.37(3H, s), 4.04(2H, s), 6.73(1H, d, J=7.9Hz), 7.12(1H, d, J=7.9Hz), 7.23-7.31(3H, m), 7.48-7.52(2H, m), 7.87(1H, s), 7.99(2H, d, J=8.3Hz), 8.47(1H, brs)
IR (Nujol): 1682 cm⁻¹

10 Example 3

Synthesis of 3-(2-chloro-4-iodobenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (11))

- According to the method used in Example 1, 3-(2-chloro-4-iodobenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (0.350 g) was obtained from 5-carboxy-3-(2-chloro-4-iodobenzyl)-2-methylindole (0.30 g), N,N'-carbonyldiimidazole (0.23 g), 1-pentanesulfonamide (0.22 g), and diazabicycloundecene (0.22 ml).
15 ¹H-NMR (DMSO-d₆, δ ppm): 0.81(3H, t, J=7.1Hz), 1.22-1.39(4H, m), 1.63-1.71(2H, m), 2.29(3H, s), 3.47(2H, t, J=7.4Hz), 4.05(2H, s),
20 6.69(1H, d, J=8.1Hz), 7.34(1H, d, J=8.3Hz), 7.52(1H, d, J=8.2Hz), 7.62(1H, d, J=8.6Hz), 7.81(1H, s), 8.02(1H, s), 11.37(1H, s), 11.69(1H, s)
mp: 188-189°C

25 Example 4

Synthesis of 3-(2-chloro-4-iodobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (12))

- According to the method used in Example 1, 3-(2-chloro-4-iodobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)-
30 indole (0.350 g) was obtained from 5-carboxy-3-(2-chloro-4-iodobenzyl)-2-methylindole (0.30 g), N,N'-carbonyldiimidazole (0.23 g), (4-methylbenzene)sulfonamide (0.24 g), and diazabicycloundecene (0.22 ml).
¹H-NMR (DMSO-d₆, δ ppm): 2.27(3H, s), 2.37(3H, s), 4.03(2H, s),
35 6.67(1H, d, J=8.1Hz), 7.30(1H, d, J=8.5Hz), 7.40(2H, d, J=8.1Hz),

7.51(1H, d, J=7.7Hz), 7.53(1H, d, J=8.2Hz), 7.81(1H, s), 7.85(2H, d, J=8.0Hz), 7.95(1H, s), 11.34(1H, s), 12.12(1H, brs)

mp: 283-285°C

5 Example 5

Synthesis of 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (13))

10 According to the method used in Example 1, 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)-indole (0.050 g) was obtained from 5-carboxy-3-(2-chloro-4-(phenylethynyl)benzyl)-2-methylindole (0.28 g), N,N'-carbonyldiimidazole (0.23 g), 1-pentanesulfonamide (0.21 g), and diazabicycloundecene (0.21 ml).

15 ¹H-NMR (DMSO-d₆, δ ppm): 0.80(3H, t, J=7.3Hz), 1.21-1.38(4H, m), 1.63-1.70(2H, m), 2.31(3H, s), 3.47(2H, t, J=7.7Hz), 4.14(2H, s), 6.98(1H, d, J=8.0Hz), 7.34-7.38(2H, m), 7.40-7.43(3H, m), 7.52-7.55(2H, m), 7.63(1H, d, J=8.5Hz), 7.66(1H, s), 8.05(1H, s), 11.39(1H, s), 11.68(1H, s)

mp: 206-207°C

20

Example 6

Synthesis of 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (14))

25 According to the method used in Example 1, 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (0.020 g) was obtained from 5-carboxy-3-((2-chloro-4-phenylethynyl)benzyl)-2-methylindole (0.28 g), N,N'-carbonyldiimidazole (0.23 g), (4-methylbenzene)sulfonamide (0.24 g), and diazabicycloundecene (0.21 ml).

30 ¹H-NMR (DMSO-d₆, δ ppm): 2.29(3H, s), 2.36(3H, s), 4.12(2H, s), 6.95(1H, d, J=8.1Hz), 7.30(1H, d, J=8.4Hz), 7.34-7.44(6H, m), 7.52-7.56(3H, m), 7.66(1H, s), 7.84(2H, d, J=7.7Hz), 7.97(1H, s), 11.35(1H, s), 12.09(1H, s)

mp: 203-205°C

35

Synthesis of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (15))

According to the method used in Example 1, white crystals
5 (0.184 g) of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-
((4-methylbenzene)sulfonylcarbamoyl)indole were obtained from 5-
carboxy-3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylindole
(0.399 g), N,N'-carbonyldiimidazole (0.242 g), (4-methyl-
benzene)sulfonamide (0.255 g), and diazabicycloundecene (0.227 g).
10 ¹H-NMR (DMSO-d₆, δ ppm): 2.37(3H, s), 2.45(3H, s), 4.10(2H, s),
6.95(1H, d, J=8.2Hz), 7.18-7.32(3H, m), 7.34-7.41(6H, m), 7.53(1H,
d), 7.57(2H, d, J=7.3Hz), 7.71(1H, s), 7.84(2H, d, J=8.3Hz), 8.00(1H,
s), 11.34(1H, s), 12.10(1H, s)
mp: 207-208.5°C

Synthesis of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (16))

According to the method used in Example 1, white crystals
20 (0.038 g) of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methylindole (0.150 g), N,N'-carbonyldiimidazole (0.091 g), 1-pentanesulfonamide (0.085 g), and diazabicycloundecene (0.085 g).
25 ¹H-NMR (DMSO-d₆, δ ppm): 0.79(3H, t, J=7.3Hz), 1.25(2H, m), 1.34(2H, m), 1.67(2H, m), 2.32(3H, s), 3.46(2H, m), 6.97(1H, d, J=8.2Hz), 7.16-7.29(3H, m), 7.33-7.42(4H, m), 7.56(2H, d, J=7.8Hz), 7.63(1H, d), 7.71(1H, s), 8.07(1H, s), 11.36(1H, s), 11.69(1H, s)
mp: 205.5-207°C

Synthesis of 3-(2-chloro-4-(2-phenylethyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (17)) .

In an atmosphere of nitrogen, platinum dioxide (0.010 g) was
35 added to a mixture of 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-

methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (0.098 g) obtained in Example 7, acetic acid (4 ml), and ethyl acetate (10 ml). The mixture was hydrogenated and stirred at room temperature for 90 minutes. The resulting solid material was removed by filtration and the filtrate was concentrated. The obtained residue was recrystallized from a mixed solvent of methanol and water to give white solid material (0.068 g) of 3-(2-chloro-4-(2-phenylethyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole.

¹H-NMR (DMSO-d₆, δ ppm): 2.27(3H, s), 2.36(3H, s), 2.81(4H, s), 4.04(2H, s), 6.83(1H, d, J=8.0Hz), 7.00-7.32(8H, m), 7.40(2H, d, J=7.3Hz), 7.53(1H, d, J=8.3Hz), 7.85(2H, d, J=8.2Hz), 7.97(1H, s), 11.31(1H, s), 12.09(1H, s)

Mass(FAB⁺): m/e 557(M+1)

mp: 207-208°C

Example 10

Synthesis of 3-(2-chloro-4-(benzyloxy)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (18))

According to the method used in Example 1, pale yellow crystals (0.120 g) of 3-(2-chloro-4-(benzyloxy)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(benzyloxy)benzyl)-2-methylindole (0.400 g), N,N'-carbonyldiimidazole (0.320 g), (4-methylbenzene)sulfonamide (0.330 g), and diazabicycloundecene (0.300 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.28(3H, s), 2.36(3H, s), 4.00(2H, s), 5.06(2H, s), 6.82(2H, d, J=1.4Hz), 7.11(1H, s), 7.27-7.42(9H, m), 7.52(1H, dd, J=8.6 and 1.7Hz), 7.84(1H, d, J=8.3Hz), 7.96(1H, s), 11.29(1H, s), 12.10(1H, brs)

mp: 173-174°C

Example 11

Synthesis of 3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (19))

According to the method used in Example 1, white crystals (0.180 g) of 3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methyl-indole (0.180 g), N,N'-carbonyldiimidazole (0.200 g), (4-methylbenzene)sulfonamide (0.220 g), and diazabicycloundecene (0.190 g).
¹H-NMR (DMSO-d₆, δ ppm): 0.94-1.03(2H, m), 1.09-1.27(3H, m), 1.58-1.78(6H, m), 2.27(3H, s), 2.37(3H, s), 3.72(2H, d, J=6.4Hz), 3.99(2H, s), 6.73(1H, dd, J=8.6 and 2.6Hz), 6.80(1H, d, J=8.7Hz), 7.00(1H, d, J=2.5Hz), 7.28(1H, d, J=8.6Hz), 7.39(2H, d, J=8.0Hz), 7.52(1H, d, J=8.5Hz), 7.84(2H, d, J=8.2Hz), 7.96(1H, s), 11.28(1H, s), 12.10(1H, brs)
mp: 167-168°C
IR (Nujol): 1683cm⁻¹

Example 12

Synthesis of 3-(2-chloro-4-phenylbenzyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-2-methylindole (compound (20))

According to the method used in Example 1, pale yellow powder (0.170 g) of 3-(2-chloro-4-phenylbenzyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-2-methylindole was obtained from 5-carboxy-3-(2-chloro-4-phenylbenzy)-2-methylindole (0.200 g), N,N'-carbonyldiimidazole (0.130 g), 5-chlorothiophene-2-sulfonamide (0.130 g), and diazabicycloundecene (0.120 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.32(3H, s), 4.13(2H, s), 6.97(1H, d, J=8.1Hz), 7.12-7.64(10H, m), 7.73(1H, d, J=1.9Hz), 8.00 (1H, s), 11.30(1H, brs), 12.50(1H, brs)
mp: 200-201°C
IR (Nujol): 1678cm⁻¹

Example 13

Synthesis of 3-(2-chloro-4-phenylbenzyl)-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-2-methylindole (compound (21))

According to the method used in Example 1, pale yellow crystals (0.390 g) of 5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-3-(2-

chloro-4-phenylbenzyl)-2-methylindole were obtained from 5-carboxy-3-(2-chloro-4-phenylbenzyl)-2-methylindole (0.270 g), N,N'-carbonyldiimidazole (0.170 g), (5-bromothiophen-2-yl)-sulfonamide (0.250 g), and diazabicycloundecene (0.160 g).

- 5 ¹H-NMR (DMSO-d₆, δ ppm): 2.33(3H, s), 4.14 (2H, s), 6.98 (1H, d, J=8.1Hz), 7.33-7.37(3H, m), 7.41-7.48(3H, m), 7.58-7.65(4H, m), 7.74(1H, d, J=1.8Hz), 8.05(1H, s), 11.40(1H, s), 12.50(1H, brs)
mp: 198-200°C
IR (Nujol): 1674cm⁻¹

10

Example 14

Synthesis of 3-(2-chloro-4-phenylbenzyl)-2-methyl-5-(4-pentenesulfonylcarbamoyl)indole (compound (22))

- 15 According to the method used in Example 1, crystals (0.105 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-(4-pentenesulfonylcarbamoyl)indole was obtained from 5-carboxy-3-(2-chloro-4-phenylbenzyl)-2-methylindole (0.200 g), N,N'-carbonyldiimidazole (0.172 g), 4-pentenesulfonamide (0.159 g), and diazabicycloundecene (0.162 g).
- 20 ¹H-NMR (DMSO-d₆, δ ppm): 1.72-1.80(2H, m), 2.09-2.15(2H, m), 2.34(3H, s), 3.47(2H, t, J=7.8Hz), 4.15(2H, s), 4.94(1H, d, J=9.9Hz), 4.99(1H, d, J=17.1Hz), 5.68-5.79(1H, m), 7.00(1H, d, J=8.0Hz), 7.37(2H, m), 7.39-7.50(3H, m), 7.63(3H, m), 7.74(1H, s), 8.09(1H, m), 11.39(1H, s), 11.73(1H, brs)
- 25 mp: 131-137°C

Example 15

Synthesis of 3-((1-bromonaphthalen-2-yl)methyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-2-methylindole (compound (23))

- 30 According to the method used in Example 1, pale brown powder (0.180 g) of 3-((1-bromonaphthalen-2-yl)methyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-2-methylindole were obtained from 3-((1-bromonaphthalen-2-yl)methyl)-5-carboxy-2-methylindole (0.210 g), N,N'-carbonyldiimidazole (0.130 g), 5-chloro-2-thiophenesulfonamide (0.130 g), and diazabicycloundecene (0.120 g).
- 35

¹H-NMR (DMSO-d₆, δ ppm): 2.31(3H, s), 4.36(2H, s), 7.10(1H, d, J=8.6Hz), 7.23(1H, d, J=4.1Hz), 7.34(1H, d, J=8.6Hz), 7.53-7.60(2H, m), 7.65-7.69(2H, m), 7.78(1H, d, J=8.5Hz), 7.89(1H, d, J=8.1Hz), 8.05 (1H, s), 8.26(1H, d, J=8.6Hz), 11.40(1H, brs), 12.50(1H, brs)

5 mp: 216-218°C

IR (Nujol): 1672cm⁻¹

Example 16

Synthesis of 3-((1-bromonaphthalen-2-yl)methyl)-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-2-methylindole (compound (24))

10 According to the method used in Example 1, pale yellow crystals (0.230 g) of 3-((1-bromonaphthalen-2-yl)methyl)-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-2-methylindole were obtained from 3-((1-bromonaphthalen-2-yl)methyl)-5-carboxy-2-methylindole

15 (0.220 g), N,N'-carbonyldiimidazole (0.150 g), 5-bromo-2-thiophenesulfonamide (0.220 g), and diazabicycloundecene (0.140 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.31(3H, s), 4.37(2H, s), 7.10(1H, d, J=8.5Hz), 7.32-7.36(2H, m), 7.55(1H, t, J=7.4Hz), 7.59(1H, d, J=8.6Hz), 7.63(1H, d, J=4.0Hz), 7.67(1H, t, J=7.7Hz), 7.78(1H, d, J=8.5Hz), 7.89(1H, d, J=8.1Hz), 8.07(1H, s), 8.27(1H, d, J=8.6Hz), 11.41(1H, brs), 12.47(1H, brs)

mp: 225.5-226.5°C

IR (Nujol): 1674cm⁻¹

25 Example 17

Synthesis of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole (compound (25))

According to the method used in Example 1, pale red powder (0.440 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole was obtained from 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylindole (0.390 g), N,N'-carbonyldiimidazole (0.290 g), (4-methylbenzene)sulfonamide (0.300 g), and diazabicycloundecene (0.270 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.27(3H, s), 2.36(3H, s), 4.04(2H, s), 6.84(1H, d, J=8.3Hz), 7.28(1H, d, J=8.6Hz), 7.35-7.40(3H, m), 7.54(1H,

d, $J=8.7\text{Hz}$), 7.71(1H, d, $J=1.9\text{Hz}$), 7.83(2H, d, $J=8.2\text{Hz}$), 7.94 (1H, s), 11.31(1H, s), 12.10(1H, brs)

mp: 226-228°C

IR (Nujol): 1682cm^{-1}

5

Example 18

Synthesis of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-vinylbenzene)sulfonylcarbamoyl)indole (compound (26))

According to the method used in Example 1, white crystals
10 (0.190 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-vinylbenzene)sulfonylcarbamoyl)indole were obtained from 3-(4-bromo-2-chloro-benzyl)-5-carboxy-2-methylindole (0.390 g), N,N'-carbonyl-diimidazole (0.290 g), (4-vinylbenzene)sulfonamide (0.320 g), and diazabicycloundecene (0.270 g).

15 $^1\text{H-NMR}$ (DMSO- d_6 , δ ppm): 2.28(3H, s), 4.05(2H, s), 5.46(1H, d, $J=10.9\text{Hz}$), 6.01(1H, d, $J=17.7\text{Hz}$), 6.78-6.86(2H, m), 7.31(1H, d, $J=8.5\text{Hz}$), 7.37(1H, dd, $J=8.4$ and 1.6Hz), 7.54(1H, d, $J=8.4\text{Hz}$), 7.69(2H, d, $J=8.4\text{Hz}$), 7.71(1H, d, $J=1.9\text{Hz}$), 7.92(2H, d, $J=8.3\text{Hz}$), 7.97 (1H, s), 11.37(1H, s), 12.16(1H, brs)

20 mp: 215°C (decomp.)

IR (Nujol): 1679cm^{-1}

Example 19

25 Synthesis of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)indole (compound (27))

According to the method used in Example 1, pale red crystals
(0.300 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)indole were obtained from 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylindole (0.390 g), N,N'-carbonyldiimidazole (0.290 g), (2-phenylethenyl)sulfonamide (0.320 g), and diazabicycloundecene (0.270 g).

35 $^1\text{H-NMR}$ (DMSO- d_6 , δ ppm): 2.28(3H, s), 4.05(2H, s), 6.83(1H, d, $J=8.4\text{Hz}$), 7.35(1H, d, $J=8.7\text{Hz}$), 7.37(1H, dd, $J=8.3$ and 2.0Hz), 7.41-7.47(3H, m), 7.48(1H, d, $J=15.4\text{Hz}$), 7.58-7.64(2H, m), 7.71(1H, d, $J=2.0\text{Hz}$), 7.73-7.76(2H, m), 8.04(1H, s), 11.37(1H, s), 11.86(1H,

brs)

mp: 204.5-205.5°C

IR (Nujol): 1674cm⁻¹

5 Example 20

Synthesis of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((1-pentene)-sulfonylcarbamoyl)indole (compound (28))

10 According to the method used in Example 1, pale yellow crystals (0.050 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((1-pentene)-sulfonylcarbamoyl)indole were obtained from 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylindole (0.390 g), N,N'-carbonyl-diimidazole (0.290 g), (1-pentene)sulfonamide (0.270 g), and diazabicycloundecene (0.270 g).

15 ¹H-NMR (DMSO-d₆, δ ppm): 0.86(3H, t, J=7.4Hz), 1.40-1.47(2H, m), 2.21(2H, quartet, J=6.6Hz), 2.29(3H, s), 4.05(2H, s), 6.76(1H, s), 6.84(1H, d, J=8.3Hz), 7.32(1H, d, J=8.5Hz), 7.37(1H, d, J=8.3Hz), 7.41-7.51(1H, m), 7.60(1H, d, J=8.4Hz), 7.71(1H, d, J=1.9Hz), 7.99(1H, s), 11.34(1H, s), 11.73(1H, brs)

mp: 163-164°C

20 IR (Nujol): 1680cm⁻¹

Example 21

Synthesis of 3-(4-bromo-2-chlorobenzyl)-5-((5-bromo-2-thiophene-sulfonyl)carbamoyl)-2-methylindole (compound (29))

25 According to the method used in Example 1, pale red crystals (0.230 g) of 3-(4-bromo-2-chlorobenzyl)-5-((5-bromo-2-thiophene-sulfonyl)carbamoyl)-2-methylindole were obtained from 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylindole (0.270 g), N,N'-carbonyldiimidazole (0.170 g), 5-bromo-2-thiophenesulfonamide (0.250 g), and diazabicycloundecene (0.160 g).

30 ¹H-NMR (DMSO-d₆, δ ppm): 2.28(3H, s), 4.06(2H, s), 6.84 (1H, d, J=8.4Hz), 7.34(1H, d, J=8.7Hz), 7.35(1H, d, J=4.1Hz), 7.38(1H, dd, J=8.4 and 2.0Hz), 7.59(1H, dd, J=8.6 and 1.7Hz), 7.65(1H, d, J=4.1Hz), 7.71(1H, d, J=2.0Hz), 7.99(1H, s), 11.41(1H, s), 12.50(1H, brs)

35 mp: 234-235°C

IR (Nujol): 1689cm⁻¹

Example 22

Synthesis of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-(4-pentene-sulfonylcarbamoyl)indole (compound (30))

According to the method used in Example 1, crystals (0.032 g) of 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-(4-pentenesulfonylcarbamoyl)indole was obtained from 3-(4-bromo-2-chlorobenzyl)-5-carboxy-2-methylindole (0.200 g), N,N'-carbonyldiimidazole (0.171 g), 4-pentenesulfonamide (0.160 g), and diazabicycloundecene (0.158 g).

¹H-NMR (DMSO-d₆, δ ppm): 1.73-1.81(2H, m), 2.11-2.16(2H, m), 2.30(3H, s), 3.47(2H, m), 4.06(2H, s), 4.99(2H, m), 5.70-5.99(1H, m), 6.86(1H, d, J=8.4Hz), 7.34(1H, d, J=8.5Hz), 7.38(1H, d, J=8.2Hz), 7.63(1H, d, J=8.3Hz), 7.72(1H, s), 8.03(1H, s), 11.38(1H, brs), 11.71(1H, brs)
mp: 145-150°C

Example 23

Synthesis of 5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole (compound (31))

According to the method used in Example 1, pale yellow crystals (0.450 g) of 5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole were obtained from 5-carboxy-3-(2,4-dichlorobenzyl)-2-methylindole (0.330 g), N,N'-carbonyldiimidazole (0.240 g), 5-chloro-2-thiophenesulfonamide (0.300 g), and diazabicycloundecene (0.230 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.29(3H, s), 4.07(2H, s), 6.91(1H, d, J=8.4Hz), 7.23-7.27(2H, m), 7.34(1H, d, J=8.5Hz), 7.58-7.61(2H, m), 7.69(1H, d, J=4.1Hz), 7.99(1H, s), 11.40(1H, s), 12.48 (1H, brs)
mp: 212-214°C

IR (Nujol): 1688cm⁻¹

Example 24

Synthesis of 5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole (compound (32))

According to the method used in Example 1, pale yellow crystals (0.460 g) of 5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole were obtained from 5-carboxy-3-(2,4-dichlorobenzyl)-2-methylindole (0.330 g), N,N'-carbonyl-diimidazole (0.240 g), 5-bromo-2-thiophenesulfonamide (0.360 g), and diazabicycloundecene (0.230 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.28(3H, s), 4.07(2H, s), 6.91(1H, d, J=8.4Hz), 7.25(1H, dd, J=8.4 and 2.2Hz), 7.34(1H, d, J=8.5Hz), 7.36(1H, d, J=4.0Hz), 7.59(1H, dd, J=8.6 and 1.6Hz), 7.61(1H, d, J=2.1Hz), 7.65(1H, d, J=4.0Hz), 8.00(1H, s), 11.41(1H, s), 12.48 (1H, brs)

mp: 231-233°C

IR (Nujol): 1688cm⁻¹

Example 25

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (33))

According to the method used in Example 1, white crystals (0.225 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.200 g), N,N'-carbonyldiimidazole (0.177 g), 1-pentanesulfonamide (0.166 g), and diazabicycloundecene (0.166 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.79(3H, t, J=7.2Hz), 1.25(2H, m), 1.34(2H, m), 1.66(2H, m), 2.31(3H, s), 3.47(2H, t, J=7.6Hz), 4.18(2H, s), 7.11(1H, d, J=8.1Hz), 7.36(1H, d, J=8.5Hz), 7.55(1H, d, J=8.1Hz), 7.63(1H, d, J=8.5Hz), 7.86(1H, s), 8.04(1H, s), 11.43(1H, s), 11.92(1H, brs)

mp: 146-150°C

Example 26

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (34))

According to the method used in Example 1, white crystals (0.220 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-

(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.200 g), N,N'-carbonyldiimidazole (0.177 g), p-toluenesulfonamide (0.187 g), and diazabicycloundecene (0.166 g).

5 $^1\text{H-NMR}$ (DMSO-d_6 , δ ppm): 2.29(3H, s), 2.37(3H, s), 4.17(2H, s), 7.09(1H, d, $J=8.1\text{Hz}$), 7.32(1H, d, $J=8.5\text{Hz}$), 7.39(2H, d, $J=8.2\text{Hz}$), 7.55(2H, d, $J=8.5\text{Hz}$), 7.84(3H, m), 7.98(1H, s), 11.41(1H, s), 12.12(1H, brs)

mp: 247-250°C

10

Example 27

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)indole (compound (35))

15 According to the method used in Example 1, white crystals (0.295 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.368 g), N,N'-carbonyldiimidazole (0.243 g), 5-chloro-2-thiophenesulfonamide (0.297 g), and diazabicycloundecene (0.228 g).

20 $^1\text{H-NMR}$ (DMSO-d_6 , δ ppm): 2.30(3H, s), 4.18(2H, s), 7.09(1H, d, $J=8.0\text{Hz}$), 7.25(1H, d, $J=4.0\text{Hz}$), 7.35(1H, d, $J=8.5\text{Hz}$), 7.55(1H, d, $J=8.2\text{Hz}$), 7.60(1H, d, $J=8.8\text{Hz}$), 7.69(1H, d, $J=4.0\text{Hz}$), 7.86(1H, s), 8.00(1H, s), 11.44(1H, s), 12.51(1H, brs)

IR: 1696cm^{-1}

25 mp: 228-230°C

Example 28

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)indole (compound (36))

30 According to the method used in Example 1, white crystals (0.425 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.368 g), N,N'-carbonyldiimidazole (0.243 g), 5-bromo-2-thiophenesulfonamide (0.363 g), and diazabicycloundecene (0.228 g).

35

5 IR: 1691cm^{-1}
mp: $247-249^{\circ}\text{C}$

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((4-vinylbenzene)sulfonylcarbamoyl)indole (compound (37))

¹H-NMR (DMSO-d₆, δ ppm): 2.29(3H, s), 4.17(2H, s), 5.45(1H, d, J=11.0Hz), 6.00(1H, d, J=17.6Hz), 6.81(1H, dd, J=17.6 and 11.0Hz), 7.09(1H, d, J=8.1Hz), 7.32(1H, d, J=8.5Hz), 7.55(2H, m), 7.68(2H, d, J=8.4Hz), 7.86(1H, s), 7.92(2H, d, J=8.4Hz), 7.98(1H, s), 11.40(1H, s), 12.15(1H, brs)
IR: 1681cm⁻¹
mp: 185-188°C

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)indole (compound (38))

According to the method used in Example 1, pale yellowish brown crystals (0.215 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbonyl)indole was obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.368 g), N,N'-carbonyldiimidazole (0.243 g), (2-phenylethenyl)sulfonamide (0.275 g), and diazabicycloundecene (0.228 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.30(3H, s), 4.18(2H, s), 7.09(1H, d, J=8.0Hz), 7.35(1H, d, J=8.5Hz), 7.44(3H, m), 7.48(1H, d, J=15.6Hz), 7.55(1H, d, J=8.0Hz), 7.61(1H, d, J=15.8Hz), 7.63(1H, m), 7.75(2H, d, J=6.5Hz), 7.876(1H, s), 8.06(1H, s), 11.41(1H, s), 11.96(1H, brs)

5 IR: 1688cm⁻¹

mp: 219-224°C

Example 31

Synthesis of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-
10 ((1-pentene)sulfonylcarbamoyl)indole (compound (39))

According to the method used in Example 1, crystals (0.105 g) of 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((1-pentene)sulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methylindole (0.368 g),
15 N,N'-carbonyldiimidazole (0.243 g), 1-pentenesulfonamide (0.224 g), and diazabicycloundecene (0.228 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.85(3H, t, J=7.4Hz), 1.43(2H, m), 2.22(2H, q, J=7.0Hz), 2.30(3H, s), 4.18(2H, s), 6.75(1H, d, J=15.2Hz), 6.82(1H, m), 7.09(1H, d, J=8.1Hz), 7.35(1H, d, J=8.5Hz), 7.55(1H, d, J=8.0Hz),
20 7.61(1H, d, J=7.3Hz), 7.86(1H, s), 8.02(1H, s), 11.41(1H, s), 11.76(1H, brs)

IR: 1674cm⁻¹

mp: 90-93°C

25 Example 32

Synthesis of 3-(2-chloro-4-(phenoxymethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (40))

According to the method used in Example 1, white crystals (0.094 g) of 3-(2-chloro-4-(phenoxymethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(phenoxymethyl)benzyl)-2-methylindole (0.179 g),
30 N,N'-carbonyldiimidazole (0.143 g), 1-pentanesulfonamide (0.134 g), and diazabicycloundecene (0.133 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.80(3H, t, J=7.2Hz), 1.26(2H, m), 1.34(2H, m), 1.67(2H, m), 2.31(3H, s), 3.47(2H, t, J=7.7Hz), 4.11(2H, s),
35

5.04(2H, s), 6.90-6.98(4H, m), 7.26(3H, m), 7.34(1H, d, J=8.6Hz),
7.53(1H, s), 7.62(1H, d, J=8.9Hz), 8.05(1H, s), 11.36(1H, s),
11.68(1H, s)

mp: 151-153°C

5

Example 33

Synthesis of 3-(2-chloro-4-(phenoxyethyl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (41))

According to the method used in Example 1, pale yellow crystals
10 (0.132 g) of 3-(2-chloro-4-(phenoxyethyl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(phenoxyethyl)benzyl)-2-methylindole (0.179 g), N,N'-carbonyldiimidazole (0.143 g), p-toluenesulfonamide (0.151 g), and diazabicycloundecene (0.133 g).

15 ¹H-NMR (DMSO-d₆, δ ppm): 2.89(3H, s), 2.36(3H, s), 4.09(2H, s), 5.04(2H, s), 6.91-6.98(4H, m), 7.22-7.31(4H, m), 7.39(2H, d, J=8.2Hz), 7.53(2H, m), 7.85(2H, d, J=8.2Hz), 7.99(1H, s), 11.34(1H, s), 12.09(1H, brs)

mp: 170-172°C

20

Example 34

Synthesis of 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (42))

According to the method used in Example 1, pale yellow oily
25 material (0.155 g) of 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole was obtained from 5-carboxy-3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methylindole (0.280 g), N,N'-carbonyldiimidazole (0.220 g), 1-pentanesulfonamide (0.205 g), and
30 diazabicycloundecene (0.205 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.81(3H, t, J=7.1Hz), 1.13-1.40(9H, m), 1.45(1H, m), 1.65(4H, m), 1.83(2H, m), 2.30(3H, s), 3.47(2H, t, J=7.6Hz), 4.09(2H, s), 4.42(2H, s), 4.53(1H, m), 6.92(1H, d, J=7.9Hz), 7.10(1H, d, J=7.9Hz), 7.34(1H, d, J=8.6Hz), 7.38(1H, s), 7.63(1H, d, J=8.5Hz), 8.05(1H, s), 11.34(1H, s), 11.68(1H, brs)

35

Example 35

Synthesis of 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (43))

5 According to the method used in Example 1, pale yellow crystals (0.140 g) of 3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(cyclohexyloxymethyl)benzyl)-2-methylindole (0.280 g), N,N'-carbonyldiimidazole (0.220 g), p-toluenesulfonamide (0.233 g), and diazabicycloundecene (0.205 g).
10 ¹H-NMR (DMSO-d₆, δ ppm): 1.15-1.30(5H, m), 1.46(1H, m), 1.64(2H, m), 1.83(2H, m), 2.28(3H, s), 2.37(3H, s), 4.07(2H, s), 4.42(2H, s), 5.53(1H, m), 6.89(1H, d, J=8.0Hz), 7.09(1H, d, J=8.0Hz), 7.30(1H, d, J=8.6Hz), 7.37(1H, s), 7.40(2H, d, J=8.1Hz), 7.53(1H, d, J=8.6Hz),
15 7.85(2H, d, J=8.3Hz), 7.98(1H, s), 11.32(1H, s), 12.09(1H, s)
mp: 178.8-180.9°C

Example 36

Synthesis of 3-(2-chloro-4-ethoxybenzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (44))

20 According to the method used in Example 1, colorless crystals (0.145 g) of 3-(2-chloro-4-ethoxybenzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-ethoxybenzyl)-2-methylindole (0.190 g), N,N'-carbonyldiimidazole (0.162 g), p-toluenesulfonamide (0.171 g), and diazabicycloundecene (0.152 g).
25 ¹H-NMR (DMSO-d₆, δ ppm): 1.27(3H, t, J=7.0Hz), 2.28(3H, s), 2.37(3H, s), 3.97(2H, q, J=7.0Hz), 4.00(2H, s), 6.73(1H, dd, J=8.6 and 2.5Hz), 6.82(1H, d, J=8.6Hz), 7.00(1H, d, J=2.5Hz), 7.29(1H, d, J=8.6Hz),
30 7.40(2H, d, J=8.2Hz), 7.52(1H, dd, J=8.5 and 1.7Hz), 7.85(2H, d, J=8.3Hz), 7.97(1H, s), 11.30(1H, s), 12.09(1H, s)
mp: 161.9-163.3°C

Example 37

35 Synthesis of 3-(2-chloro-4-ethoxybenzyl)-2-methyl-5-(1-pentane-

sulfonylcarbamoyl)indole (compound (45))

According to the method used in Example 1, colorless crystals (0.090 g) of 3-(2-chloro-4-ethoxybenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-ethoxybenzyl)-2-methylindole (0.190 g), N,N'-carbonyldiimidazole (0.162 g), 1-pentanesulfonamide (0.151 g), and diazabicycloundecene (0.152 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.81(3H, t, J=7.3Hz), 1.27(5H, m), 1.35(2H, m), 1.67(2H, m), 2.29(3H, s), 3.47(2H, t, J=7.7Hz), 3.97(2H, q, J=6.9Hz), 4.02(2H, s), 6.74(1H, dd, J=8.6 and 2.0Hz), 6.84(1H, d, J=8.6Hz), 7.00(1H, d, J=2.0Hz), 7.33(1H, d, J=8.5Hz), 7.61(1H, d, J=8.5Hz), 8.04(1H, s), 11.32(1H, s), 11.68(1H, s)

mp: 103.0-105.5°C

Example 38

Synthesis of 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (46))

According to the method used in Example 1, colorless crystals (0.045 g) of 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methylindole (0.115 g), N,N'-carbonyldiimidazole (0.073 g), p-toluenesulfonamide (0.077 g), and diazabicycloundecene (0.069 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.30(3H, s), 2.35(3H, s), 4.10(2H, s), 6.95(1H, d, J=8.1Hz), 7.12(1H, dd, J=3.7 and 5.0Hz), 7.30(1H, d, J=8.5Hz), 7.37(2H, d, J=8.2Hz), 7.44(1H, dd, J=1.8 and 8.1Hz), 7.51-7.56(3H, m), 7.73(1H, d, J=1.9Hz), 7.84(2H, d, J=8.3Hz), 8.00(1H, s), 11.34(1H, s), 12.12(1H, brs)

mp: 236.5-242.0°C

Example 39

Synthesis of 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (47))

According to the method used in Example 1, colorless crystals (0.067 g) of 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-

(1-pentanesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methylindole (0.160 g), N,N'-carbonyldiimidazole (0.102 g), 1-pentanesulfonamide (0.095 g), and diazabicycloundecene (0.096 g).

5 ¹H-NMR (DMSO-d₆, δ ppm): 0.79(3H, t, J=7.3Hz), 1.24(2H, m), 1.33(2H, m), 1.66(2H, m), 2.32(3H, s), 3.46(2H, t, J=7.7Hz), 4.12(2H, s), 6.97(1H, d, J=8.1Hz), 7.11(1H, dd, J=4.0 and 4.9Hz), 7.35(1H, d, J=8.5Hz), 7.44(1H, dd, J=1.8 and 8.0Hz), 7.52(1H, d, J=3.2Hz), 7.54(1H, d, J=5.1Hz), 7.63(1H, dd, J=1.5 and 8.5Hz), 7.73(1H, d, J=1.8Hz), 8.07(1H, s), 11.37(1H, s), 11.69(1H, brs)
10 mp: 184.4-185.1°C

Example 40

Synthesis of 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (48))
15

According to the method used in Example 1, white crystals (0.170 g) of 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(1-pentane-sulfonylcarbamoyl)indole was obtained from 5-carboxy-3-(2-chloro-4-(furan-2-yl)benzyl)-2-methylindole (0.250 g), N,N'-carbonyldiimidazole (0.162 g), 1-pentanesulfonamide (0.151 g), and diazabicycloundecene (0.152 g).
20

¹H-NMR (DMSO-d₆, δ ppm): 0.79(3H, t, J=7.3Hz), 1.24(2H, m), 1.33(2H, m), 1.65(2H, m), 2.32(3H, s), 3.45(2H, t, J=7.6Hz), 4.12(2H, s), 6.57(1H, m), 6.97(1H, d, J=3.2Hz), 7.00(1H, d, J=8.1Hz), 7.34(1H, d, J=8.5Hz), 7.49(1H, d, J=8.1Hz), 7.62(1H, d, J=8.6Hz), 7.72(1H, s), 7.76(1H, s), 8.06(1H, s), 11.35(1H, s), 11.70(1H, brs)
25 mp: 162.1-163.8°C
IR: 1652cm⁻¹

Example 41

Synthesis of 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (49))
30

According to the method used in Example 1, white crystals (0.260 g) of 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-
35

(2-chloro-4-(furan-2-yl)benzyl)-2-methylindole (0.250 g), N,N'-carbonyldiimidazole (0.162 g), p-toluenesulfonamide (0.171 g), and diazabicycloundecene (0.152 g).

¹H-NMR (DMSO-d₆, δ ppm): 2.30(3H, s), 2.35(3H, s), 4.10(2H, s), 6.58(1H, m), 6.98(2H, m), 7.30(1H, d, J=8.6Hz), 7.38(2H, d, J=8.1Hz), 7.49(1H, d, J=7.9Hz), 7.53(1H, d, J=8.4Hz), 7.73(1H, s), 7.77(1H, s), 7.84(2H, d, J=8.1Hz), 8.00(1H, s), 11.34(1H, s), 12.12(1H, brs)
mp: 232.7-234.1°C
IR: 1679cm⁻¹

Example 42

Synthesis of 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole and 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole (compound (50))

According to the method used in Example 1, pale yellow crystals (0.067 g) of a mixture containing, at an abundance ratio of about 2:8, of 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole and 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole were obtained from 5-carboxy-3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methylindole (0.100 g) containing 5-carboxy-3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methylindole, N,N'-carbonyldiimidazole (0.064 g), p-toluenesulfonamide (0.067 g), and diazabicycloundecene (0.060 g).

¹H-NMR (DMSO-d₆, δ ppm): 0.87(3H, m), 1.28-1.61(4H, m), 1.91-2.14(2H, m), 2.28(3H, s), 2.37(3H, s), 4.08(2H, m), 5.05-5.48(1H, m), 5.80/6.30(1H, m), 6.80-7.00(1H, m), 7.17-7.26(1H, m), 7.29(1H, d, J=8.3Hz), 7.39(2H, d, J=7.5Hz), 7.42-7.48(1H, m), 7.53(1H, d, J=8.2Hz), 7.85(2H, d, J=7.8Hz), 7.98(1H, s), 11.31(1H, s), 12.10(1H, brs)

mp: 173-183°C

IR: 1659cm⁻¹

Example 43

Synthesis of 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole and 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole (compound (51))

5 According to the method used in Example 1, pale yellow crystals (0.062 g) of a mixture containing, at an abundance ratio of about 2:8, of 3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole and 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole were
10 obtained from 5-carboxy-3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methylindole (0.100 g) containing 5-carboxy-3-(2-chloro-4-(1-hexen-2-yl)benzyl)-2-methylindole, N,N'-carbonyldiimidazole (0.064 g), 1-pentanesulfonamide (0.060 g), and diazabicycloundecene (0.060 g).

15 ¹H-NMR (DMSO-d₆, δ ppm): 0.78-0.91(6H, m), 1.20-1.61(8H, m), 1.66(2H, m), 1.91-2.45(2H, m), 2.30(3H, m), 3.47(2H, t, J=7.6Hz), 4.07(2H, m), 5.05-5.82(1H, m), 6.28-6.99(2H, m), 7.16-7.29(1H, m), 7.34(1H, d, J=8.4Hz), 7.42-7.63(2H, m), 8.05(1H, m), 11.33(1H, s), 11.68(1H, s)

20 mp: 84-85°C

IR: 1666cm⁻¹

Test Example: Test for activity of decreasing plasma glucose using db/db mice

25

Test compounds

3-(1-bromonaphthalen-2-ylmethyl)-5-((5-chloro-2-thiophenylsulfonyl)carbamoyl)-2-methylindole (compound (23))

30 Animal used

Five-week-old female mice [C57BL/KsJ-dbm db+/db+, C57BL/KsJ-dbm +m/+m (Jackson Laboratory)] were purchased, and were kept for 2 to 3 weeks. Then, these mice were used in the test.

35 Preparation of an agent

A test compound was mixed with a powdered chow (CE-2, made by Nippon Clea) using a mortar. The mixing ratio was 0.01%. The mixed chow was changed twice a week for each group. The feed amount and the remaining amount were recorded, and the intake was calculated from the difference therebetween.

Test schedule

The female db/db mice were grouped according to the body weight, the plasma glucose, and the plasma triglyceride concentrations. Then, the mixture containing the test compound was administered to the mice for 14 days (from 8 to 10 weeks old). In the morning on day 7 and day 14, the blood was collected from the orbital venous plexus using heparinized glass capillary tubes (Chase Heparinized Capillary Tubes), and a plasma fraction was obtained through centrifugal separation. Plasma glucose, triglyceride, and insulin concentrations were measured on day 0 and day 14 as well as plasma glucose and triglyceride concentrations on day 7. The body weight was measured on day 0, day 7, and day 14. After the final collection of the blood, the mice was killed using CO₂ gas.

Measurement method

The plasma glucose was measured by a glucose oxidase method (Glucose CII-Test Wako made by Wako Pure Chemical Industries, Ltd.) using from 10 to 15 μ l of plasma. The plasma triglyceride concentration was measured by a GPO-p-chlorophenol method (Triglyceride G-Test Wako made by Wako Pure Chemical Industries, Ltd.) or a GPO-DAOS method (Triglyceride E-Test Wako) using from 10 to 15 μ l of plasma. The above-mentioned measurements were conducted immediately after the blood collection. The plasma insulin concentration was measured by radio immuno assay method (Phadesef Insulin RIA Kit made by Cabi Pharmacia) using 20 μ l of plasma (which can be stored at -20°C).

Results

The difference in the plasma glucose and the plasma triglyceride concentrations between the groups of the db/db mouse and the +/+ mouse was defined as 100%, and the rate (%) of decrease in the plasma glucose and the plasma triglyceride concentrations of the group to which the test compound was administered was calculated. As a result, when the test compound was administered at a dose of 3.2 mg/kg, plasma glucose decreasing activity was 19%, while TG concentration-decreasing activity was 9%.


10 INDUSTRIAL APPLICABILITY

Novel indole derivatives and their pharmaceutically acceptable salts are provided. These compounds and their pharmaceutically acceptable salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful for preventing and treating impaired glucose tolerance, diabetes (type II diabetes), diabetic complications (e.g., diabetic gangrene, diabetic arthropathy, diabetic osteopenia, diabetic glomerulosclerosis, diabetic nephropathy, diabetic dermatopathy, diabetic neuropathy, diabetic cataract, diabetic retinopathy, etc.), syndrome of insulin resistance (e.g., insulin receptor disorders, Rabson-Mendenhall syndrome, leprechaunism, Kobberling-Dunnigan syndrome, Seip syndrome, Lawrence syndrome, Cushing syndrome, acromegaly, etc.), polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular disorders (e.g., stenocardia, cardiac failure, etc.), hyperglycemia (e.g., abnormal saccharometabolism such as feeding disorders, etc.), hypertension, pulmonary hypertension, congestive heart failure, glomerulopathy (e.g., diabetic glomerulosclerosis, etc.), tubulointerstitial disorders (e.g., renopathy induced by FK506, cyclosporin, etc.), renal failure, angiostenosis (e.g., after percutaneous arterioplasty), distal angiopathy, cerebral apoplexy, chronic reversible obstructions (e.g., bronchitis, asthma (chronic asthma, allergic asthma), etc.), autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders (e.g., hypersensitive enteropathy syndrome, etc.), impotence (e.g., organic impotence, psychic impotence, etc.),

nephritis, cachexia(e.g., progressive weight loss due to the lipolysis, myolysis, anemia, edema, anorexia, etc. associated with chronic diseases such as cancer, tuberculosis, endocrine disorder, AIDS, etc.), pancreatitis, or restenosis after PTCA.

Claims

1. An indole derivative represented by formula (I) or a salt thereof:



wherein R_1 represents an aryl lower alkyl group, said aryl group may
 10 be substituted with one or more groups selected from the group
 consisting of a halogen atom, an aryl group, a heterocyclic group,
 an aryl lower alkyl group, an aryl lower alkenyl group, a halo-lower
 alkyl group, a lower cycloalkyl-lower alkoxy group, a lower
 cycloalkoxy-lower alkyl group, an aryl lower alkynyl group, an
 15 aryloxy lower alkyl group, an aryl lower alkoxy group, a lower
 alkylthio group, a lower alkoxy group, and an alkenyl group; and
 R_2 represents a lower alkyl group, a lower alkenyl group, an aryl
 group, or a heterocyclic group, each of which may be substituted with
 a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an
 20 aryl group.

2. The indole derivative or a salt thereof according to claim
 1, wherein R_1 is a halo-aryl lower alkyl group, said aryl group may
 be substituted with a halo-lower alkyl group, a lower cycloalkyl lower
 alkoxy group, a lower cycloalkoxy lower alkyl group, an aryl lower
 25 alkynyl group, an aryloxy lower alkyl group, a lower alkylthio group,
 a lower alkoxy group, or a lower alkenyl group.

3. The indole derivative or a salt thereof according to claim
 1, wherein said derivative is selected from the group consisting of
 3-(2-chloro-4-(t-butylthio)benzyl)-2-methyl-5-(1-pentane-
 30 sulfonylcarbamoyl)indole, 3-(2-chloro-4-(t-butylthio)benzyl)-2-
 methyl-5-(4-methylbenzene)sulfonylcarbamoyl)indole, 3-(2-chloro-
 4-iodo-benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-
 (2-chloro-4-iodobenzyl)-2-methyl-5-((4-methyl-benzene)sulfonyl-
 carbamoyl)indole, 3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-
 35 5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-chloro-4-(phenyl-

ethynyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)-
indole, 3-(2-chloro-4-(2-phenylethenyl)benzyl)-2-methyl-5-((4-
methylbenzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(2-phenyl-
ethenyl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole,
5 3-(2-chloro-4-(2-phenylethyl)benzyl)-2-methyl-5-((4-methyl-
benzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(benzyloxy)-
benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole,
3-(2-chloro-4-(cyclohexylmethyloxy)benzyl)-2-methyl-5-((4-
methylbenzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-phenyl-
10 benzyl)-5-((5-chloro-2-thiophenesulfonyl)carbamoyl)-2-methyl-
indole, 3-(2-chloro-4-phenylbenzyl)-5-((5-bromo-2-thiophene-
sulfonyl)carbamoyl)-2-methylindole, 3-(2-chloro-4-phenylbenzyl)-
2-methyl-5-(4-pentenesulfonylcarbamoyl)indole, 3-((1-bromo-
naphthalen-2-yl)methyl)-5-((5-chloro-2-thiophenesulfonyl)-
15 carbamoyl)-2-methylindole, 3-((1-bromonaphthalen-2-yl)methyl)-5-
((5-bromo-2-thiophenesulfonyl)carbamoyl)-2-methylindole, 3-(4-
bromo-2-chlorobenzyl)-2-methyl-5-((4-methylbenzene)sulfonyl-
carbamoyl)indole, 3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-
vinylbenzene)sulfonylcarbamoyl)indole, 3-(4-bromo-2-chloro-
20 benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)indole,
3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((1-pentene)sulfonyl-
carbamoyl)indole, 3-(4-bromo-2-chlorobenzyl)-5-((5-bromo-2-
thiophenesulfonyl)carbamoyl)-2-methylindole, 3-(4-bromo-2-
chlorobenzyl)-2-methyl-5-(4-pentenesulfonylcarbamoyl)indole, 5-
25 ((5-chloro-2-thiophenesulfonyl)carbamoyl)-3-(2,4-dichloro-
benzyl)-2-methylindole, 5-((5-bromo-2-thiophenesulfonyl)-
carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole, 3-(2-chloro-4-
(trifluoromethyl)benzyl)-2-methyl-5-(1-pentanesulfonyl-
carbamoyl)indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-
30 methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-
4-(trifluoromethyl)benzyl)-2-methyl-5-((5-chloro-2-thiophene-
sulfonyl)carbamoyl)indole, 3-(2-chloro-4-(trifluoromethyl)-
benzyl)-2-methyl-5-((5-bromo-2-thiophenesulfonyl)carbamoyl)-
indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((4-
35 vinylbenzene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(trifluoro-


methyl)benzyl)-2-methyl-5-((2-phenylethenyl)sulfonylcarbamoyl)-
 indole, 3-(2-chloro-4-(trifluoromethyl)benzyl)-2-methyl-5-((1-
 pentene)sulfonylcarbamoyl)indole, 3-(2-chloro-4-(phenoxymethyl)-
 benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 5 chloro-4-(phenoxymethyl)benzyl)-2-methyl-5-(4-methylbenzene-
 sulfonylcarbamoyl)indole, 3-(2-chloro-4-(cyclohexyloxymethyl)-
 benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 chloro-4-(cyclohexyloxymethyl)benzyl)-2-methyl-5-(4-methyl-
 benzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-ethoxybenzyl)-2-
 10 methyl-5-(4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-
 4-ethoxybenzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole,
 3-(2-chloro-4-(thiophen-2-yl)benzyl)-2-methyl-5-(4-methyl-
 benzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(thiophen-2-
 yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole, 3-(2-
 15 chloro-4-(furan-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonyl-
 carbamoyl)indole, 3-(2-chloro-4-(furan-2-yl)benzyl)-2-methyl-5-
 (4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(1-
 hexen-2-yl)benzyl)-2-methyl-5-(4-methylbenzenesulfonyl-
 carbamoyl)indole, 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-
 20 (4-methylbenzenesulfonylcarbamoyl)indole, 3-(2-chloro-4-(1-
 hexen-2-yl)benzyl)-2-methyl-5-(1-pentanesulfonylcarbamoyl)indole,
 and 3-(2-chloro-4-(1-hexen-1-yl)benzyl)-2-methyl-5-(1-pentane-
 sulfonylcarbamoyl)indole.

4. A pharmaceutical composition for preventing and treating
 25 impaired glucose tolerance, diabetes, diabetic complications,
 syndrome of insulin resistance, polycystic ovary syndrome,
 hyperlipidemia, atherosclerosis, cardiovascular disorders,
 hyperglycemia, hypertension, pulmonary hypertension, congestive
 heart failure, glomerulopathy, tubulointerstitial disorders, renal
 30 failure, angiostenosis, distal angiopathy, cerebral apoplexy,
 chronic reversible obstructions, autoimmune diseases, allergic
 rhinitis, urticaria, glaucoma, diseases characterized by
 enteromotility disorders, impotence, nephritis, cachexia,
 pancreatitis, or restenosis after PTCA, which comprises, as an active
 35 ingredient, the indole derivative or a salt thereof according to any

one of claims 1 to 3.


5. A method of producing the indole derivative of claim 1, the method comprising the steps of:

(a) reacting a compound of formula (2):




10 wherein R₃ represents a lower-alkyl group, with haloid or silane, and aldehyde corresponding to R₁ (R₁ has the same meaning as in claim 1);

(b) hydrolyzing a compound of formula (3) obtained in step (a):



wherein R₁ has the same meaning as in claim 1; and


(c) reacting a carboxyl group-activating agent and subsequently sulfonamide with a compound of formula (4) obtained in step (b):



25 wherein R₁ has the same meaning as in claim 1.

6. A method of producing the indole derivative of claim 1, the method comprising the steps of:


(a) reacting a compound of formula (2):



wherein R₃ represents a lower-alkyl group, with haloid or silane, and aldehyde corresponding to R₁ (R₁ has the same meaning as in claim 1);


35 (b) hydrolyzing a compound of formula (3) obtained in step (a):

57




wherein R_1 has the same meaning as in claim 1;

(g) reacting a halogenating agent with a compound of formula (4) obtained in step (b):



wherein R_1 has the same meaning as in claim 1; and


(h) reacting sulfonamide with a compound of formula (8) obtained in step (g):



wherein Z represents a halogen atom and R_1 has the same meaning as in claim 1.


7. A method of producing the indole derivative of claim 1, the method comprising the steps of:

(a) reacting a compound of formula (2):




wherein R_3 represents a lower-alkyl group, with haloid or silane, and aldehyde corresponding to R_1 (R_1 has the same meaning as in claim 1);

(b) hydrolyzing a compound of formula (3) obtained in step (a):



5 wherein R_1 has the same meaning as in claim 1;

(g) reacting a halogenating agent with a compound of formula (4) obtained in step (b):




10

wherein R_1 has the same meaning as in claim 1;

(i) reacting ammonia or aqueous ammonia with a compound of formula (8) obtained in step (g):

15




20

wherein Z represents a halogen atom and R_1 has the same meaning as in claim 1; and

(j) reacting sulfonylhalide to a compound of formula (9) obtained in step (i):


25



30 wherein R_1 has the same meaning as in claim 1.

Abstract

A novel indole derivative or a salt thereof is provided, which is represented by the formula:



10




wherein R_1 represents an aryl lower alkyl group, said aryl group may be substituted with one or more groups selected from the group consisting of a halogen atom, an aryl group, a heterocyclic group, an aryl lower alkyl group, an aryl lower alkenyl group, a halo-lower alkyl group, a lower cycloalkyl-lower alkoxy group, a lower cycloalkoxy-lower alkyl group, an aryl lower alkynyl group, an aryloxy lower alkyl group, an aryl lower alkoxy group, a lower alkylthio group, a lower alkoxy group, and an alkenyl group; and R_2 represents a lower alkyl group, a lower alkenyl group, an aryl group, or a heterocyclic group, each of which may be substituted with a hydrogen atom, a lower alkyl group, a lower alkenyl group, or an aryl group. The compound of the present invention has blood sugar level-depressing activity and PDE5-inhibiting activity, and is useful as medicine.

15

20


1 / 15

Figure 1




2 / 15


Figure 2



(12)




(13)




(14)

3/15


Figure 3



(15)




(16)




(17)

4/15


Figure 4



(18)




(19)




(20)

5/15


Figure 5



(21)




(22)




(23)

6/15


Figure 6



(24)




(25)




(26)

7/15


Figure 7



(27)




(28)




(29)

8 / 15


Figure 8



(30)




(31)




(32)

9/15


Figure 9



(33)






(34)



(35)




10/15

Figure 10



12/15

Figure 12



13/15

Figure 13









Figure 14



(4 8)




(4 9)



(5 0)

15/15

Figure 15



SUPPLEMENTAL COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled INDOLE DERIVATIVES, the specification of which:

- ☐ is attached hereto.
☒ was filed on October 4, 2000 as Application Serial No. 09/647,772 and was amended on _____.
☐ was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed	
PCT	PCT/JP99/01798	April 5, 1999	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
Japan	10/93625	April 6, 1998	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Reg. No. 34,819
 Timothy A. French, Reg. No. 30,175
 Ralph A. Mittelberger, Reg. No. 33,195
 Jeffrey D. Hsi, Reg. No. 40,024

John W. Freeman, Reg. No. 29,066
 Anita L. Meiklejohn, Reg. No. 35,283
 John F. Hayden, Reg. No. 37,640

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon. I hereby declare that Noriko Oku, Chikako Oku, and Tomohito Oku are "all the heirs" of deceased inventor Teruo Oku.

Attorney's Docket No.: 06501-065001

SUPPLEMENTAL COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled INDOLE DERIVATIVES, the specification of which:

- ☐ is attached hereto.
☒ was filed on October 4, 2000 as Application Serial No. 09/647,772 and was amended on _____.
☐ was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed	
PCT	PCT/JP99/01798	April 5, 1999	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
Japan	10/93625	April 6, 1998	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Reg. No. 34,819
 Timothy A. French, Reg. No. 30,175
 Ralph A. Mittelberger, Reg. No. 33,195
 Jeffrey D. Hsi, Reg. No. 40,024

John W. Freeman, Reg. No. 29,066
 Anita L. Meiklejohn, Reg. No. 35,283
 John F. Hayden, Reg. No. 37,640

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon. I hereby declare that Noriko Oku, Chikako Oku, and Tomohito Oku are "all the heirs" of deceased inventor Tcruo Oku.

Supplemental Combined Declaration and Power of Attorney

Page 2 of 4 Pages

1-00 Full Name of Inventor: NORITSUGU YAMASAKIInventor's Signature: Noritsugu YamasakiDate: 20th May 2002Residence Address: 1049-32, Kamae, Shikama-ku, Himeji-shiHyogo 672-8071JPXJAPANCitizenship: JapanPost Office Address: 1049-32, Kamae, Shikama-ku, Himeji-shiHyogo 672-8071JAPAN2-00 Full Name of Inventor: TAKAFUMI IMOTOInventor's Signature: Takafumi ImotoDate: 20th May 2002Residence Address: 30-2-5, Arai, Arai-shiNiigata 944-0041JPXJAPANCitizenship: JapanPost Office Address: 30-2-5, Arai, Arai-shiNiigata 944-0041JAPANFull Name of Inventor: TERUO OKU (Deceased)Inventor's Signature: Deceased

Date: _____

Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shiOsaka 569-1117JAPANCitizenship: JapanPost Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shiOsaka 569-1117JAPANFull Name of Inventor: NORIKO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____

Date: _____

Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shiOsaka 569-1117JAPANCitizenship: JapanPost Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shiOsaka 569-1117JAPAN

Supplemental Combined Declaration and Power of Attorney

Page 2 of 4 Pages

Full Name of Inventor: NORITSUGU YAMASAKI

Inventor's Signature: _____

Date: _____

Residence Address: 1049-32, Kamae, Shikama-ku, Himeji-shi
Hyogo 672-8071
JAPAN

Citizenship: Japan

Post Office Address: 1049-32, Kamae, Shikama-ku, Himeji-shi
Hyogo 672-8071
JAPAN

Full Name of Inventor: TAKAFUMI IMOTO

Inventor's Signature: _____

Date: _____

Residence Address: 30-2-5, Arai, Arai-shi
Niigata 944-0041
JAPAN

Citizenship: Japan

Post Office Address: 30-2-5, Arai, Arai-shi
Niigata 944-0041
JAPAN

Full Name of Inventor: TERUO OKU (Deceased)

Inventor's Signature: _____

Date: _____

Residence Address: Deceased
2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Full Name of Inventor: NORIKO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: Noriko Oku

Date: September 26, 2001

Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117 JPX
JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Supplemental Combined Declaration and Power of Attorney

Page 3 of 4 Pages

5-11
Full Name of Inventor: CHIKAKO OKU (As Representative of Teruo Oku (Deceased))
Inventor's Signature: Chikako Oku Date: September 26, 2001
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi JPX
Osaka 569-1117
JAPAN
Citizenship: Japan
Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

6-11
Full Name of Inventor: TOMOHITO OKU (As Representative of Teruo Oku (Deceased))
Inventor's Signature: Tomohito Oku Date: 10/10/01
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117 JPX
JAPAN
Citizenship: Japan
Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Full Name of Inventor: HIROSHI KAYAKIRI
Inventor's Signature: _____ Date: _____
Residence Address: 7-11, Aobaokaminami, Suita-shi
Osaka 565-0802
JAPAN
Citizenship: Japan
Post Office Address: 7-11, Aobaokaminami, Suita-shi
Osaka 565-0802
JAPAN

Full Name of Inventor: OSAMU ONOMURA
Inventor's Signature: _____ Date: _____
Residence Address: 19-1-502, Yanagawa-machi, Nagasaki-shi
Nagasaki 852-8013
JAPAN
Citizenship: Japan
Post Office Address: 19-1-502, Yanagawa-machi, Nagasaki-shi
Nagasaki 852-8013
JAPAN

Supplemental Combined Declaration and Power of Attorney
Page 4 of 4 Pages

Full Name of Inventor: TAKAHIRO HIRAMURA

Inventor's Signature: _____

Date: _____

Residence Address: 1-17-11, Takayanagi, Arai-shi
Niigata 944-0013

JAPAN

Citizenship: Japan

Post Office Address: 1-17-11, Takayanagi, Arai-shi
Niigata 944-0013
JAPAN

20158519.2.doc

SUPPLEMENTAL COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled INDOLE DERIVATIVES, the specification of which:

- ☐ is attached hereto.
☒ was filed on October 4, 2000 as Application Serial No. 09/647,772 and was amended on _____
☐ was described and claimed in PCT International Application No. _____ filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
WIPO	PCT/JP99/01798	April 5, 1999	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Japan	10/93625	April 6, 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Janis K. Fraser, Reg. No. 34,819	John W. Freeman, Reg. No. 29,066
Timothy A. French, Reg. No. 30,175	Anita L. Meiklejohn, Reg. No. 35,283
Ralph A. Mittelberger, Reg. No. 33,195	John F. Hayden, Reg. No. 37,640
Jeffrey D. Hsi, Reg. No. 40,024	

Address all telephone calls to JANIS K. FRASER, PH.D., J.D. at telephone number (617) 542-5070.

Address all correspondence to JANIS K. FRASER, PH.D., J.D. at:

FISH & RICHARDSON P.C.
225 Franklin Street
Boston, MA 02110-2804

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon. I hereby declare that Noriko Oku, Chikako Oku, and Tomohito Oku are "all the heirs" of deceased inventor Teruo Oku.

Supplemental Combined Declaration and Power of Attorney

Page 2 of 4 Pages

Full Name of Inventor: NORITSUGU YAMASAKI

Inventor's Signature: _____ Date: _____
Residence Address: 1049-32, Kamae, Shikama-ku, Himeji-shi
Hyogo 672-8071
JAPAN
Citizenship: Japan
Post Office Address: 1049-32, Kamae, Shikama-ku, Himeji-shi
Hyogo 672-8071
JAPAN

Full Name of Inventor: TAKAFUMI IMOTO

Inventor's Signature: _____ Date: _____
Residence Address: 30-20-5, Arai, Arai-shi
Niigata 944-0041
JAPAN
Citizenship: Japan
Post Office Address: 30-20-5, Arai, Arai-shi
Niigata 944-0041
JAPAN

Full Name of Inventor: TERUO OKU (Deceased)

Inventor's Signature: Deceased Date: _____
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN
Citizenship: Japan
Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Full Name of Inventor: NORIKO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____ Date: _____
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN
Citizenship: Japan
Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Supplemental Combined Declaration and Power of Attorney

Page 3 of 4 Pages

Full Name of Inventor: CHIKAOKU OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____

Date: _____

Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Full Name of Inventor: TOMOHIITO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____

Date: _____

Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Full Name of Inventor: HIROSHI KAYAKIRI

Inventor's Signature: Hiroshi KayakiriDate: May 16, 2002

Residence Address: 7-11, Aobaokaminami, Suita-shi

Osaka 565-0802

JAPAN

Citizenship: Japan

Post Office Address: 7-11, Aobaokaminami, Suita-shi

Osaka 565-0802

JAPAN

Full Name of Inventor: OSAMU ONOMURA

Inventor's Signature: _____

Date: _____

Residence Address: 19-1-502, Yanagawa-machi, Nagasaki-shi

Nagasaki 852-8013

JAPAN

Citizenship: Japan

Post Office Address: 19-1-502, Yanagawa-machi, Nagasaki-shi

Nagasaki 852-8013

JAPAN

7-01

Supplemental Combined Declaration and Power of Attorney
Page 3 of 4 Pages

Full Name of Inventor: CHIKAKO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____ Date: _____
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Full Name of Inventor: TOMOHITO OKU (As Representative of Teruo Oku (Deceased))

Inventor's Signature: _____ Date: _____
Residence Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi

Osaka 569-1117

JAPAN

Citizenship: Japan

Post Office Address: 2-4-1-504, Tenjin-machi, Takatsuki-shi
Osaka 569-1117
JAPAN

Full Name of Inventor: HIROSHI KAYAKIRI

Inventor's Signature: _____ Date: _____
Residence Address: 7-11, Aobaokaminami, Suita-shi

Osaka 565-0802

JAPAN

Citizenship: Japan

Post Office Address: 7-11, Aobaokaminami, Suita-shi
Osaka 565-0802
JAPAN

8-00 Full Name of Inventor: OSAMU ONOMURA

Inventor's Signature: Osamu Onomura Date: May 21, 2002
Residence Address: 19-1-502, Yanagawa-machi, Nagasaki-shi

Nagasaki 852-8013

JAPAN JPX

Citizenship: Japan

Post Office Address: 19-1-502, Yanagawa-machi, Nagasaki-shi
Nagasaki 852-8013
JAPAN

Supplemental Combined Declaration and Power of Attorney
Page 4 of 4 Pages

Full Name of Inventor: TAKAHIRO HIRAMURA

Inventor's Signature: _____ Date: _____
Residence Address: 1-17-11, Takayanagi, Arai-shi
Niigata 944-0013
JAPAN
Citizenship: Japan
Post Office Address: 1-17-11, Takayanagi, Arai-shi
Niigata 944-0013
JAPAN

201585192.doc

Supplemental Combined Declaration and Power of Attorney

Page 4 of 4 Pages

9-00 Full Name of Inventor: TAKAHIRO HIRAMURAInventor's Signature: Takahiro HiramuraDate: 28th May 2002Residence Address: 1-17-11, Takayanagi, Arai-shiNiigata 944-0013JAPAN

JPK

Citizenship: JapanPost Office Address: 1-17-11, Takayanagi, Arai-shiNiigata 944-0013JAPAN